1   **Metallo-β-lactamases: structure, function, epidemiology, treatment options, and the**

2   **development pipeline**

3

4   Sara E Boyd[1], David M Livermore[2], David C. Hooper[3], William W Hope[1]

5

6   [1] Antimicrobial Pharmacodynamics and Therapeutics, Department of Molecular and Clinical

7   Pharmacology, University of Liverpool, Liverpool, L69 3GE

8   [2] Norwich Medical School, University of East Anglia, Norwich, NR4 7TJ

9   [3] Division of Infectious Diseases, Massachusetts General Hospital, Harvard Medical School,

10   Boston, MA 02114

11

12   Corresponding author:

13   Dr Sara E Boyd MRCP DTMH MBChB

14   Antimicrobial Pharmacodynamics and Therapeutics, Department of Molecular and Clinical

15   Pharmacology, University of Liverpool, Liverpool, L69 3GE

16   Telephone: +441517945941

17   Email: s.e.boyd@liverpool.ac.uk

18

19   **Key words:** metallo-β-lactamase, treatment, pharmacology, drug development

20   **Running title:** Treatment options for infections caused by bacteria that produce metallo β-

21   lactamases

22

23

24

25   Abstract

26   Modern medicine is threatened by the global rise of antibiotic resistance, especially among -

27   negative bacteria. Metallo-β-lactamase (MBL) enzymes are a particular concern and are

28   increasingly disseminated worldwide, though particularly in Asia. Many producers have

29   multiple further drug resistances, leaving few obvious treatment options. Nonetheless, and

30   more encouragingly, MBLs may be less effective agents of carbapenem resistance *in vivo*,

31   under zinc limitation, than *in vitro*. Owing to their unique structure and function, and their

32   diversity, MBLs pose a particular challenge for drug development. They evade all recently

33   licensed β-lactam- β-lactamase inhibitor combinations, although several stable agents and

34   inhibitor combinations are at various stages in the pipeline. These potential therapies, along

35   with the epidemiology of producers and current treatment options, are the focus of this

36   review.

37

Introduction

Antimicrobial therapy is threatened by the global rise of resistance, especially in gram-negative bacteria (1), where resistance to β-lactams is largely mediated by β-lactamases (2). Carbapenems evade most β-lactamases but are hydrolyzed by metallo-β-lactamases (MBLs) as well as by a few active-site serine β-lactamases (SBLs), notably members of the KPC and OXA-48-like groups. MBLs are chromosomal and ubiquitous in some non-fermenters, including *Stenotrophomonas maltophilia*, *Aeromonas* spp*.* and *Chryseobacterium* spp., which are of modest clinical concern. A minority of *Bacteroides fragilis* strains have a chromosomal MBL, CfiA or CcrA, but this is uncommon and only expressed strongly if an upstream insertion sequence provides an efficient promoter (3). More important are the acquired MBLs that are spreading among Enterobacterales and *Pseudomonas aeruginosa* (4); these are associated with extremely-drug-resistant (XDR) phenotypes, with the producers generally also resistant to multiple aminoglycosides, fluoroquinolones, and other agents as well as to β-lactams.

Classification and diversity of metallo-β-lactamases

β-Lactamases are classified by two major systems. The first is based on substrate profiles and vulnerability to inhibitors (5), and places MBLs into its Group 3, whereas Groups 1 and 2 comprise SBLs. The second classifies β-lactamases according to their amino acid sequences, recognising four enzyme classes (6). MBLs form class B whilst SBLs divide among classes A, C and D (7). The MBLs are structurally and mechanistically dissimilar from SBLs, suggesting a separate evolutionary origin.

Class B is further divided into three subclasses, B1, B2 and B3, based on differences in amino acid sequence at the active site, zinc ligands, zinc stoichiometry, loop architecture, and substrate profiles (8). The important acquired MBLs, comprising the IMP, NDM and VIM types

62 fall into subclass B1. They hydrolyze all currently available β-lactam antibiotics except

63 monobactams (e.g. aztreonam) (9), as do most or all other sub-class B1 or B3 enzymes. In

64 contrast, the CphA (subclass B2) MBLs of *Aeromonas* spp. have narrow-spectrum activity

65 directed exclusively against carbapenems. Irrespective of subclass, MBLs are not inhibited by

66 clavulanic acid, sulbactam, tazobactam, avibactam or by developmental penicillanic acid

67 sulfones and diazabicyclooctanes.

68   The important acquired subgroup B1 MBLs (Table 1) are mostly named based on where

69 they were first described; thus, for example, Verona Integron-encoded Metallo β-lactamase

70 (VIM) and New Delhi Metallo β-lactamase (NDM). The first acquired MBL ('imipenemase', IMP-

71 1), was reported from clinical isolates of *P. aeruginosa* and *Serratia marcescens* in Japan in the

72 1990s (10) and its family now includes over 85 sequence variants (11). The first VIM enzyme

73 was found in *P. aeruginosa* in 1997 (12), with over 69 variants since described (11). NDM –

74 now the most prevalent MBL in Enterobacterales and *A. baumannii* – was first identified in

75 2008 in *Klebsiella pneumoniae* and *Escherichia coli* isolates from a patient who had travelled

76 to Sweden from New Delhi, India (13). Twenty-nine NDM variants have since been described,

77 (11).

78   It is easy to be dismissive of the chromosomal subclass B2 and B3 MBLs, but recent

79 reports highlight *Stenotrophomonas maltophilia* as a multidrug-resistant pathogen in

80 immunocompromised hosts (14). *S. maltophilia* carries a subclass B3 MBL (L1 enzyme), which

81 is unique among MBLs in having four identical subunits (15), in addition to a chromosomally-

82 mediated SBL (L2 enzyme). This combination confers resistance to almost all β-lactams,

83 although minimum inhibitory concentrations (MICs) vary with methodology, because media

84 affect the expression and/or function of these enzymes (16). *Elizabethkingia meningoseptica*

85   has two chromosomal MBLs, a B1 enzyme (BlaB) and a B3 type (GOB) with the former making

86   the dominant contribution to resistance (17).

87

88   **Genetic support of acquired MBLs**

89   Acquired IMP and VIM enzymes generally are encoded by gene cassettes within class 1 or class

90   3 integrons. These may be embedded within transposons, allowing insertion into the bacterial

91   chromosome or plasmids (18). By contrast, the bla_{NDM} gene is not integron-associated and has

92   been observed on narrow-host-range plasmids belonging to incompatibility group IncF, in

93   addition to wide-host-range plasmids belonging to IncA/C, IncL/M, IncH and IncN (19–22). *K.*

94   *pneumoniae* and *E. coli* are the frequent hosts of these plasmids, and there are particular

95   associations with *K. pneumoniae* sequence types (STs) ST11, ST14, ST15 or ST147 and *E. coli*

96   ST167, ST410 or ST617 (23). These should not, however, be seen as global epidemic strains

97   along the lines of *K. pneumoniae* ST258 variants with KPC carbapenemases, for many are

98   common STs without carbapenemases. In *A. baumannii* the bla_{NDM-1} gene is generally located

99   within the composite transposon Tn*125* and embedded between two copies of a strong

100   promoter gene IS*Aba125* (24, 25); it is much less prevalent in this genus than are OXA

101   carbapenemases (Class D).

102   B2 and B3 MBLs are generally chromosomally encoded, ubiquitous in their host species

103   and not transmissible. However, exceptions exist, with horizontal transfer observed. Thus, the

104   AIM-1 MBL (B3) was initially reported, in 2012, to be encoded by a gene inserted in (and

105   atypical of) the chromosome of a *P. aeruginosa* isolate; subsequently, in 2019, it was reported

106   from *K. pneumoniae* (26). The bla_{LMB-1} gene, encoding another subclass B3 enzyme, was

107   reported to be located on a plasmid in *Rheinheimera pacifica* where it was flanked by ISCR

108   mobilization sequences, implying transfer from some other (unknown) source organism. (27).

109   Mobilization of bla_{SMB-1}, encoding a third sub-class B3 enzyme, has occurred similarly (28).

110

111   **Structure and catalytic function of MBLs**

112   Irrespective of subgroup, MBLs contain the αβ/βα fold typical of the metallo-hydrolase /

113   oxidoreductase superfamily (29). The *S. maltophilia* enzyme has four identical subunits (15),

114   whereas other MBLs are monomeric.

115   B1 and B3 MBLs have a shallow active-site groove containing 1 or 2 catalytically

116   functional divalent zinc ions, flanked by flexible loops (29). In contrast, the B2 enzymes have

117   an active site that is less accessible and flanked by a helix (30). Except for these consistencies,

118   MBLs are highly divergent even within subclasses, and have as little as 20% sequence identity

119   between subclasses (7).

120   Mechanistically, the zinc ion(s) activate a water molecule, which acts to open the β-

121   lactam ring (31). There is no covalent intermediate, as with SBL-mediated catalysis. Anionic

122   intermediates have been characterized when MBLs hydrolyze carbapenems (32), but not when

123   NDM-1 enzymes hydrolyze penicillins or cephalosporins (33). In general, imipenem and

124   meropenem are similarly good substrate for MBLs: for example, NDM-1 enzyme displays

125   similar catalytic activity, reflected in values of k_{cat}/K_m ratio, for imipenem (0.09μM^{-1}s^{-1}) and

126   meropenem (0.06μM^{-1}s^{-1}) (34); biapenem is a weaker substrate, owing to high K_m values, but

127   seems unsuitable for high-dose development (35).

128   Figure 1 illustrates the amino acid residues that bind zinc at the active sites of B1, B2,

129   and B3 MBLs (8). Crystal structures of B1 enzymes, including IMP-, VIM-, NDM-, and *B. fragilis*

130   CcrA, (panel A) reveal two zinc-binding sites (Zn1 and Zn2). The Zn1 site contains three histidine

131   residues (His116, His118, and His196), whereas the ligands for the Zn2 site are aspartic acid

6

132   (Asp120), cysteine (Cys221), and histidine (His263) (8). There is only one zinc ion in the active

133   site of the *A. hydrophila* enzyme (subclass B2, panel B), and two in the active site of the *S.*

134   *maltophilia* enzyme (subclass B3, panel C).

135   Differences in assay methodology between workers make it difficult to compare

136   hydrolytic efficiencies for different MBLs. Variation within e.g. the VIM, IMP, SPM and GIM

137   family appears largely inconsequential (36). Nevertheless, subtle but important evolution

138   may be ongoing, as illustrated in the NDM family. Here, experimental data do not define

139   major differences in the catalytic efficiencies among NDM -1, -3, -4, -5, -6, -7 and -8 enzymes

140   (37) under standard conditions, but differences are seen under zinc deprivation. Thus,

141   studies comparing NDM-1, NDM-4 (Met154Leu) and NDM-12 (Met154Leu, Gly222Asp)

142   demonstrate that the Met154Leu substitution, present in 50% of clinical NDM variants in

143   some locales, enhances the ability to confer resistance at low Zn^{++} concentrations (38, 39).

144   This is potentially important because, as discussed later, zinc is restricted in infection (40) and

145   its scarcity may impede the ability of classical NDM-1 enzyme to confer clinical resistance.

146   NDM variants that have increased affinity for zinc (up to ~10-fold decreased $K_{d, Zn2}$) display

147   selective advantages in experiments that mimic zinc scarcity imposed by the host immune

148   system (41). Perhaps driven by similar pressures, the NDM-15 variant has evolved to function

149   efficiently as a mono- rather than a bi-zinc enzyme (41). In addition, there are suggestions

150   that NDM enzymes are evolving to develop greater thermodynamic stability (37).

151

152   **Epidemiology and distribution of acquired MBLs**

153   Bacteria with IMP, VIM and NDM enzymes have been identified in a range of community,

154   hospital, and environmental settings (42). Their prevalence, and importance relative to serine

155   carbapenemases varies greatly by country.

156

Indian Subcontinent, Asia and Russia. The greatest burden of acquired, plasmid-mediated,

MBLs lies in south and south-east Asia (43), where NDM types are prevalent. As already noted,

bla_{NDM-1} was first identified in bacteria isolated in 2008 from a patient who had travelled to

Sweden from India (44). NDM variants have subsequently been spread worldwide via patient

transfers and travel (45). Epidemiological surveillance has confirmed that NDM-1 and its

variants are widely disseminated throughout India, Pakistan and Bangladesh (46, 47);

moreover, a review of 39 carbapenem-resistant Enterobacterales (CRE) collected in India in

2006-2007 by the SENTRY Antimicrobial Surveillance Program found that 15 harboured bla_{NDM-1}

(48), indicating that it was circulating prior to its 'discovery' in 2008. Enterobacterales with

bla_{NDM} were isolated from public tap water in India (49) and in river systems around pilgrimage

sites (42) demonstrating the gene has become established beyond healthcare environments.

In India there is frequent co-carriage with other carbapenemases in Enterobacterales

(50); thus, in 2012, among 113 non-clonal CRE isolates at a Mumbai hospital, 106 produced

NDM enzymes and 21 of these also have a second carbapenemase, most often an OXA-48-like

(n=17) or VIM-type (n=4). Surprisingly, given that most international reports of NDM enzymes

relate to Enterobacterales, *P. aeruginosa* was the most common MBL host (24%) among 3414

carbapenem-resistant gram-negative bacteria collected from community and hospital settings

in North India (51), with bla_{NDM-1} (36%) the most prevalent carbapenemase gene followed by

bla_{VIM} (18.4%).

Although KPC is the principal carbapenemase among Enterobacterales (CPE) in China,

a survey across 25 provinces showed that 32% of phenotypic carbapenem resistance in

Enterobacterales was linked to bla_{NDM-1} (52) whilst a study (2012-16) of clinical *Enterobacter*

cloacae across three tertiary hospitals found bla_{NDM-1} to be the most common carbapenemase

180 gene (80%), followed by bla_{IMP-26} (8%) and bla_{IMP-4} (6%) (53). The importance of IMP MBLs,

181 particularly IMP-4, in China has been underscored by others; thus, multiple Enterobacterales

182 species carrying a plasmid encoding IMP-4 enzyme were identified from patients with

183 epidemiological links to China (54), and surveillance at a Beijing hospital highlighted both IMP-

184 4 and NDM-1 in *K. pneumoniae* (55). Co-localisation of bla_{NDM-9} and the plasmid-mediated

185 colistin resistance gene *mcr-1* was seen in an *E. coli* strain recovered from retail chicken meat

186 in Guangzhou, China (56). Having been recognized 30 years ago in Japan, IMP-type enzymes

187 are now endemic there, though not highly prevalent (57).

188   NDM MBLs are the second-most-prevalent carbapenemases after OXA-48 in the

189 Middle East, excepting Israel (58, 59). This probably reflects extensive interactions with the

190 Indian subcontinent. As in India, there is significant penetration of bla_{NDM} into *P. aeruginosa*,

191 where a much greater proportion of carbapenem resistance appears to be carbapenemase-

192 mediated than in Europe or the USA. Thus, in the Gulf Cooperation Council countries, bla_{VIM}

193 was found in 39% of carbapenem-resistant *P. aeruginosa* isolates (60), with most hosts

194 belonging to internationally-disseminated high risk clones, including ST235, ST111, ST233,

195 ST654 and ST357 (60). These lineages seem unusually adept at acquiring extrinsic resistance

196 genes. In Dubai, 32% of resistant *P. aeruginosa* isolates produced VIM-type MBLs (61), though

197 a larger proportion had outer membrane impermeability.

198   The proportion of carbapenem-resistant *P. aeruginosa* harboring MBLs in Russia rose

199 from 4.5% between 2002-04 to 28.7% between 2008-10 (62), largely reflecting the spread of

200 an XDR bla_{VIM-2}-positive ST235 high-risk clone, also present in Belarus and Kazakhstan (62).

201 NDM is reported as the predominant carbapenemase among Enterobacterales in St Petersburg

202 (63, 64), whereas OXA-48 is predominant in Moscow (65).

203

204   **Europe**. Although Italy had earlier reported both IMP and VIM enzymes (66), Greece was the

205   first European country to report extensive dissemination of Enterobacterales with MBLs.

206   Specifically , *K. pneumoniae* with VIM carbapenemases were reported from multiple hospitals

207   in 2003–7, and multi-locus sequence typing identified three major clonal complexes (CCs);

208   CC147, CC18 and CC14 among the producers (67). By 2006, 20% of *K. pneumoniae* isolates

209   collected from hospital wards and 50% of those from ICUs monitored by the Greek System for

210   the Surveillance of Antimicrobial Resistance were carbapenem-resistant, largely owing to the

211   spread of the bla_{VIM-1} cassette (68). By 2010, KPC had displaced VIM to become the dominant

212   carbapenemase in Greece, largely through the spread of a *K. pneumoniae* ST258 variant (69).

213   Nonetheless, VIM-types remained scattered, and may now be re-emerging due to suppression

214   of the KPC carbapenemases via the use of ceftazidime-avibactam (70).

215   Elsewhere in Europe concern about carbapenemases grew following a flurry of press

216   interest in NDM enzymes from 2008-10, and with the spread of *K. pneumoniae* ST258/512

217   lineages with KPC carbapenemases in Italy from 2010. The UK, taken as an exemplar, recorded

218   a few *P. aeruginosa* and Enterobacterales with IMP and VIM MBLs before 2008. Thereafter,

219   Enterobacterales with NDM enzymes increased (46). Most early cases were imports via

220   patients who had travelled to (and often been hospitalized in) the Indian sub-continent.

221   Multiple NDM variants have subsequently been reported in the UK, with NDM-1 the most

222   frequent among Enterobacterales, followed by NDM-5 and NDM-7 (71). In contrast, VIM

223   variants account for 91% of the (uncommon) MBLs in *P. aeruginosa*, again associated with

224   international high-risk clones ST235, ST111, ST233 and ST357 (72).

225   While referral of CPE isolates to the national reference laboratory has increased 100-

226   fold since 2008, many producers are from screening rather than clinical samples. OXA-48 is

227   now the fastest-spreading carbapenemase but isolates with NDM enzymes account for 20-25%

228   of CPE submitted. A growing minority of these, particularly *E. coli*, have both NDM- and OXA-

229   48-like enzymes (71, 73).

230   In 2012, the European Centre for Disease Prevention and Control launched its

231   'European Survey of Carbapenemase-Producing Enterobacteriaceae (EuSCAPE)' project. The

232   geographic distribution of enzyme types were estimated by national experts across 38

233   European countries in 2015 (74). A random sample of carbapenem-susceptible and -non-

234   susceptible *K. pneumoniae* and *E. coli* subsequently were collected prospectively to determine

235   the occurrence of carbapenemases (75). The results, published in 2017, revealed SBLs (KPC or

236   OXA-48 enzymes) were more prevalent than MBLs in most countries but that MBLs were

237   widely scattered and were the most prevalent carbapenemases among Enterobacterales in a

238   few countries. Thus, VIM enzymes were the dominant carbapenemases in Hungary and NDM

239   in Serbia and Montenegro. The prevalence of NDM enzymes in the latter countries tallies with

240   early descriptions of producers linked to these Balkan states. It is unclear whether these

241   originated as imports from India or as independent local gene escapes from the unknown

242   source organism (76).

243

244   **North America**. Infections due to Enterobacterales carrying bla_{VIM-2}, bla_{VIM-7}, bla_{IMP-4} and bla_{IMP-18} genes were recorded in the USA prior to 2005 but, in general, MBLs remained extremely rare

246   (1, 77). In 2010, Enterobacterales harboring NDM-1 were isolated from three patients in

247   different states (78) and, as with many contemporaneous cases in the UK and elsewhere, the

248   source patients had all recently been in India or Pakistan (21). Subsequent expansion of NDM

249   enzymes in the US has been less marked than the UK, with KPC carbapenemases becoming

250   considerably more prevalent. Nevertheless, up to December 2017, 379 CPE with NDM

251 carbapenemases were reported to the CDC from 34 States, with just under a third (109) from

252 Illinois (79), where an outbreak was associated with contaminated endoscopes.

253   Enterobacterales with NDM enzymes have been increasing in Canada since 2008 and

254 these MBLs are now the second-most-common carbapenemases in the country, with a higher

255 prevalence in the Western Provinces (80). Surveillance conducted between 2007-2015 in

256 Toronto revealed that, among 291 clinical CPE, 51% had NDM enzymes, and 24% of these

257 patients had never received healthcare abroad nor travelled to high-risk areas (81), suggesting

258 the enzymes are established locally. In 2019 a novel MBL, bla_{CAM-1}, was identified from isolates

259 that were collected in 2007 (82). No subsequent isolates harboring this gene have been

260 reported.

261

262 **Africa**. Paucity of data means the prevalence of CPE carrying MBLs in Africa is difficult to

263 estimate. Apparent infrequency may reflect true rarity, limited sampling, or a lack of

264 infrastructure for accurate detection. CPE with VIM MBLs nonetheless have been identified in

265 Nigeria, Morocco, Algeria, Tunisia, Tanzania, and South Africa; and those with NDM enzymes

266 in Kenya, Nigeria, Morocco, Algeria, Tunisia, Tanzania, and South Africa (83, 84). Infections

267 caused by Enterobacterales producing MBLs are reported from both imported and local cases,

268 raising concerns regarding emerging endemicity (85). Those with IMP-type enzymes have been

269 identified in small numbers in Morocco, Tunisia, and Tanzania, and appear genuinely

270 uncommon (84). An outbreak caused by *Klebsiella* spp. carrying bla_{NDM-5} was reported from a

271 neonatal unit in Nigeria (86). A concern is that African patients are strongly represented in

272 medical tourism to India, which is a risk factor for colonisation with Enterobacterales producing

273 MBLs (87).

274

275 **Rest of the world**. KPC enzymes dominate among carbapenemases from Enterobacterales in

276 Latin America, with (unusually) some penetration also into *P. aeruginosa*. Nonetheless,

277 Enterobacterales with NDM enzymes are endemic in Brazil, with several outbreaks reported

278 (88). Early case reports of MBL-producing Enterobacterales in Latin America often concerned

279 Proteeae, including *Providencia* spp. and *Morganella* (89, 90), which are infrequent hosts of

280 bla_{NDM} elsewhere. This creates a treatment issue since these genera are inherently resistant to

281 polymyxins and newer-generation tetracyclines, which remain options against other MBL-

282 producing Enterobacterales (below).

283 Unique to South America is the wide distribution in Brazil of *P. aeruginosa* with SPM-1

284 MBL (91), principally associated with an ST277 clone. Outcomes of severe infections with this

285 clone are often poor, reflecting a lack of good treatment options (92).

286 Carbapenemases are rare in Australasia, but there is spread of bla_{IMP-4} among

287 Enterobacterales (93), as in parts of China. *E. cloacae* is a major host, with dissemination

288 mediated by an IncHI2 plasmid (94). Production of IMP-4 enzyme has also been recorded in

289 *Salmonella* spp. from domestic pets (95) and seagulls (96), but the significance of this is

290 uncertain.

291

292 **MBL function in resistance, *in vitro* and *in vivo***

293 For many years MBLs were perceived as clinically unimportant chromosomally-encoded

294 enzymes from non-pathogenic organisms, notably *Bacillus cereus* (97, 98). This perception

295 changed with recognition that MBLs confer much of the resistance seen in *Chryseobacterium*

296 spp. and *E. meningoseptica* (99) and with heightened awareness of the morbidity and mortality

297 associated with *S. maltophilia* bacteraemia (100, 101). Interest then escalated with the

298   discovery and proliferation of acquired MBLs, especially NDM-1, which drew extensive press

299   coverage in 2010.

300   Many MBL producers are broadly resistant *in vitro* and, on this basis, real concern exists

301   about lack of treatments. On the other hand, there is evidence that *in vivo* resistance to

302   carbapenems may be less than it appears *in vitro*, because susceptibility tests are

303   conventionally done in media (e.g. cation-adjusted Mueller-Hinton broth) with high zinc

304   concentrations (102), whereas the host immune system imposes a state of zinc deprivation in

305   infection (40, 103). This lack of zinc may not only impede the catalytic function of MBLs but

306   may also interfere with their protein folding (102) and may promote degradation of the

307   enzyme in the periplasm (104).

308   Several preclinical studies suggest a disconnect between high-level *in-vitro* resistance

309   to carbapenems associated with NDM-1 enzymes, but a weak ability to protect against

310   carbapenems in standard murine infection models (105). Moreover, NDM enzymes appear less

311   effective than other carbapenemases in causing resistance to carbapenems in patients (106,

312   107). Thus, mortality in severe infections due to Enterobacterales with bla_{NDM} appears

313   relatively low, ranging from 13% (108) - 55% (109), when compared to that seen with bacteria

314   expressing other MBLs (18% to 67%) (13), or KPC carbapenemases (41% to 65%) (110, 111).

315   Good clinical outcomes have been reported despite treatment with agents to which NDM

316   enzymes confer resistance *in vitro* (106, 107, 112). As yet, there are no studies that confirm or

317   refute whether the higher numbered NDM alleles, encoding variants with their greater affinity

318   for zinc (above), are better able to cause clinical resistance than NDM-1 (39, 41).

319   Finally, it should be underscored that whilst these indications that NDM MBLs are less

320   potent *in vivo* are intriguing, they should be approached with caution. Double-blinded

321   randomized-controlled trials have not been conducted, and existing outcome data are subject

322 to various biases (113, 114). For VIM MBLs, clinical outcomes correlate with carbapenem MICs,

323 implying little or no such *in vitro/in vivo* discordance (115).

324

325 **Current treatment options**

326 Limited data exist to inform clinicians on the optimal treatment for infections caused by MBL-

327 producing gram-negative bacteria (106). Co-trimoxazole remains the standard of care for

328 infections due to *S. maltophilia,* but most Enterobacterales with acquired MBLs also have *sul*

329 and *dfr* genes, conferring resistance. Resistances to fluoroquinolones and aminoglycosides are

330 often present alongside genes encoding acquired MBLs. In particular, bla_{NDM} genes are often

331 linked to the genes encoding ArmA or RmtB methyltransferases, which modify ribosomes to

332 block binding of aminoglycosides, including plazomicin; bla_{IMP} and bla_{VIM} generally occur within

333 integrons that often also carry *aac(6')*, encoding an acetyltransferase that compromises

334 amikacin and tobramycin, though not gentamicin or plazomicin (116). A thorough review of

335 treatment options for MDR and XDR Enterobacterales is available (117). This highlights

336 observational studies comparing monotherapy to combination therapy for bloodstream

337 infection (BSI) involving CRE, although few of these were specifically identified as having MBLs

338 (118, 119).

339

340 **Colistin**. Colistin is the current mainstay of treatment for infections due to MBL-producers. A

341 multinational survey of MBL-producing Enterobacterales and *P. aeruginosa* conducted from 2012-

342 2014 found >97% susceptibility among MBL-producing *P. aeruginosa* (variously with IMP-, VIM-

343 and NDM- enzymes), and >85% for MBL-producing Enterobacterales (>86.1% NDM-type,

344 >88.9% IMP-type >88.9% IMP-type) (83). Exceptions are *Proteeae* and *Serratia* spp., which

345 have intrinsic polymyxin resistance.

346   For bacteria harboring KPC and OXA-48 carbapenemases, colistin has recently been

347   shown less effective than microbiologically-active β-lactamases inhibitor combinations (120),

348   making it plausible that an active β-lactam likewise would be more efficacious than colistin

349   against MBL producers. Of note, the emergence of colistin resistance during treatment, with

350   secondary transmission of resistant variants is a concern (121, 122).

351

352   **Tigecycline, omadacycline and eravacycline**. These tetracyclines have strong *in vitro* activity

353   against many MBL-producing Enterobacterales, except *Proteeae*, although not against *P.*

354   *aeruginosa*. During November 2018, 275 unique Enterobacterales isolates carrying bla_{NDM}

355   collected by the US Centers for Disease Control were tested with tigecycline (86.5%

356   susceptible, based on a ≤2 μg/ml FDA breakpoint), eravacycline (66.2% susceptible, based on

357   a ≤0.5 μg/ml FDA breakpoint) and omadacycline (59.6% susceptible, based on a ≤4 μg/ml

358   breakpoint) (123). The higher susceptibility rate for tigecycline than eravacycline reflects the

359   higher FDA breakpoint for Enterobacterales; in Europe both agents have an identical 0.5 μg/ml

360   breakpoint and eravacycline is the more active on a simple gravimetric basis, though it is

361   unclear whether this confers clinical advantage (124). Merits of omadacycline are its minimal

362   known drug interactions and that it can be administered orally (125), however, it has the least

363   relevant license (for community-acquired bacterial pneumonia and acute bacterial skin and

364   skin structure infections) in relation to the clinical burden of MBL producers.

365   Whilst the *in vitro* activity of these tetracyclines is encouraging, there are multiple

366   caveats. First, tigecycline carries an FDA 'black box' warning of increased mortality when the

367   drug was used as monotherapy (126); second, both tigecycline and eravacycline have failed to

368   achieve non-inferiority to comparators in one or more clinical trials (VAP and diabetic foot

369   infection for tigecycline, cUTI for eravacycline); third, there is little provenance for tetracyclines

370   as monotherapy in the severely-ill patients who commonly develop infections due to MBL-

371   producing opportunists; fourth, particularly for tigecycline, the disparity between EUCAST (S

372    $\leq$0.5 μg/ml) and FDA (S $\leq$2 μg/ml) breakpoints creates categorization uncertainty; last, the lack

373   of anti-*Proteeae* activity is important in Latin America, where *Providencia* spp. are frequent

374   hosts of *bla*$_{NDM}$ (127). Given these uncertainties, the best advice is to consider these

375   tetracyclines in combination against MBL producers, not as monotherapy.

376

377   **Aztreonam**. Aztreonam is stable to MBLs, though activity is lost against organisms that co-

378   produce ESBLs or AmpC enzymes (128), which are common in MBL-producing

379   Enterobacterales. Clinical experience as monotherapy is lacking for MBL producers, although

380   some success has been recorded when aztreonam was used in combination with ceftazidime-

381   avibactam (129, 130), with avibactam serving to inhibit ESBLs. Six out of ten patients survived

382   following treatment with this combination during an outbreak of *K. pneumoniae* with NDM-1,

383   OXA-48, and CTX-15 β-lactamases in Barcelona (129). Although no adverse events were

384   reported, the safety is unclear, and it is difficult to match the 1.5g +0.5g q6h regimen of

385   aztreonam-avibactam that is presently being developed (below).

386

387   **Fosfomycin**. Fosfomycin commonly retains full *in vitro* activity against MBL-producing

388   Enterobacterales, and has been successful trialed, very recently, as an IV agent in cUTI (131).

389   It may be an option against MBL producers - particularly *E. coli*, which is more susceptible than

390   other Enterobacterales - but it is mainly advocated for use in combination due to concerns

391   about emergence of resistance, particularly in *Klebsiella* spp. (132). Fosfomycin has little direct

392   antipseudomonal activity, with typical MICs above breakpoints. However, *in vitro* synergy is

393 seen when fosfomycin is combined with meropenem against MBL-producing *P. aeruginosa*

394 strains (133), suggesting a need for *in-vivo* exploration.

395

396 ## Development Pipeline

397 The development pipeline represents four main strategies against MBL producers: (i)

398 protection of MBL-stable-monobactams from other co-produced β-lactamases, as e.g. with

399 aztreonam-avibactam; (ii) development of β-lactams stable to MBLs as well as SBLs, as with

400 e.g. cefiderocol and BOS-228, (iii) combinations of cephalosporins and carbapenems with

401 triple-action diazabicyclooctanes (DBOs), and (iv) direct inhibition of MBLs with cyclic

402 boronates, thiols, chelators, dicarboxylic acids, and other agents.

403

404 ## Aztreonam-avibactam

405 Aztreonam-avibactam is the first antibiotic to be developed under a public-private partnership

406 agreement (134, 135), with partial finance from the European Union's Innovative Medicine's

407 Initiative and, latterly, also the US Biomedical Advanced Research and Developmental

408 Authority (BARDA). A prospective randomized phase 3 study (NCT03580044) begins in 2020

409 to determine efficacy, safety, and tolerability versus best available therapy (BAT) for

410 hospitalized adults with complicated intra-abdominal infections (cIAI), nosocomial pneumonia

411 (NP), complicated UTI, or BSI due to MBL-producing gram-negative bacteria (135).

412 Aztreonam evades hydrolysis by MBLs (128) but is compromised by the ESBL and AmpC

413 enzymes that are co-produced by many MBL-positive CPE. These SBLs are inhibited by

414 avibactam, a diazabicyclooctane (DBO) (136, 137) and, consequently, MBL-producing

415 Enterobacterales that also carry ESBLs or AmpC are susceptible to aztreonam-avibactam *in*

416 *vitro* (138) and *in vivo* (139). The combination is less reliably active against MBL-producing *P.*

417 *aeruginosa* (140), because aztreonam has weak anti-pseudomonal activity.

418 Considerable interest exists, because the safety and efficacy of aztreonam are well

419 established, and because avibactam was established to be effective at inactivating ESBLs and

420 AmpC enzymes during trials with ceftazidime. Moreover, case reports suggest success against

421 infections caused by MBL producers when aztreonam was co-administered with ceftazidime-

422 avibactam (see aztreonam section above) (129, 130).

423

424 **MBL-stable β-lactams**

425 **Cefiderocol (S-649266).**   Cefiderocol (S-649266) is a novel parenteral siderophore

426 cephalosporin designed by Shionogi & Co. Ltd., with a catechol linked to its 3-position side

427 chain. It is licensed in the USA for cUTI and in the EU and UK for 'treatment of infections due

428 to aerobic gram-negative organisms in adults with limited treatment options' (141). It is

429 retained among developmental agents here, rather than being included in the established

430 treatments, because there is little published experience with MBL producers to date (142,

431 143).

432 Critically, the catechol moiety forms a chelation complex with ferric iron and this

433 complex is actively accumulated by gram-negative bacteria, which are forced to scavenge this

434 essential element (144). Cefiderocol has good activity *in vitro* under iron starvation, against

435 gram-negative bacteria, including CPE, *P. aeruginosa* and *A. baumannii* (145)*.* It is relatively

436 stable to both SBLs and MBLs (144), however, the MICs for Enterobacterales and non-

437 fermenters with NDM carbapenemases tend to be slightly higher than those for isolates of the

438 same species with other carbapenemase types (146). Cefiderocol proved effective against

439 carbapenem-resistant *P. aeruginosa* (expressing IMP-1 enzymes), *A. baumannii* (expressing

440 OXA-51-like enzymes) and *K. pneumoniae* (expressing NDM-1 enzymes) in immunocompetent

441 rat respiratory tract infection models, achieving a ≥3-log reduction in the number of viable

442 bacteria in the lungs when dosed over 4 days so as to recreate the human exposures of a 2g

443 q8h 3h-IV infusion regimen (147). Efficacy reduced when the infusion time was reduced to 1h,

444 owing to a lower percentage of the dosing interval during which free-drug concentrations were

445 above the MIC (% T_f >MIC) (147). Interestingly, the mean % T_f >MIC required for a 1-$\log_{10}$

446 reduction was 18-24% greater for *A. baumannii* isolates (expressing OXA-23 or OXA-24) in the

447 murine lung infection model than for Enterobacterales expressing NDM-1, NDM-4 or KPC-2

448 enzymes and for *P. aeruginosa* isolates expressing IMP-1 or VIM-10 MBLs (148).

449 In humans, the 2g IV q8h 3h-infusion regimen provided >90% probability of target

450 attainment (PTA) with 75% T_f>MIC for MICs of ≤4µg/ml for patients with normal renal function

451 (149). A phase 3 trial (NCT03032380) has shown non-inferiority to meropenem in nosocomial

452 pneumonia (150). Less encouragingly, another trial (NCT02714595), found excess deaths in the

453 cefiderocol arm, compared with 'best available therapy,' for patients with severe infections

454 caused by carbapenem-resistant gram-negative pathogens (151). Full analysis is awaited but,

455 notably, deaths were mostly associated with *Acinetobacter* infections (152), not

456 Enterobacterales.

457

458 **BOS-228 (formerly LYS228).** BOS-228 is a monobactam and, like aztreonam, is stable to MBLs

459 (153). Unlike aztreonam, it is also stable to many potent SBLs, including carbapenemases,

460 ESBLs, and AmpC types (154); moreover it binds strongly to PBPs1a and 1b of Enterobacterales

461 as well as to PBP3, which is the sole target of aztreonam (155). BOS-228 had an MIC_{90} of 2

462 µg/ml for a clinical panel of 88 Enterobacterales isolates expressing ESBLs, KPCs and MBLs

463 (153) and no single-step mutants were selected from 12 β-lactamase-expressing

464   Enterobacterales exposed to the drug at 8 x MIC, though mutants were selected from 2/12

465   strains, neither of which expressed MBLs, at 4 x MIC (155).

466   A randomized evaluator-blinded multi-center phase 2 trial (NCT03354754) to evaluate

467   pharmacokinetics, clinical responses, safety, and tolerability of BOS-228 in cIAI commenced in

468   2018. The drug is being administered as IV monotherapy (without metronidazole) q6h for at

469   least 5 days and compared to standard of care, with outcomes evaluated at day 28. A

470   randomized controlled evaluator-blinded multi-center trial (NCT03377426) in cUTI has also

471   been initiated.

472

473   **Cephalosporins or carbapenems combined with triple-action DBOs**

474   **Zidebactam and nacubactam.** Unlike with cyclic boronates (see below), it has not been possible

475   to discover DBOs that directly inhibit MBLs. However, nacubactam and zidebactam are DBO

476   analogs that combine inhibition of SBLs with direct antibacterial activity by inhibiting PBP2

477   (156). When combined with PBP3-targetted β-lactams, this attack on PBP2 leads to an

478   'enhancer' effect, with further β-lactamase-inhibition-independent synergy observed (156,

479   157). Consequently, cefepime-zidebactam and cefepime- or meropenem- nacubactam

480   combinations are active *in vitro* against >75% of MBL-producing Enterobacterales and, in

481   cefepime-zidebactam's case, also against many MBL-producing *P. aeruginosa* (158).

482   Although the direct antibacterial activity of nacubactam and zidebactam is readily lost

483   via mutations compensating for inhibition of PBP2 (159), the enhancer effect is retained, with

484   many of the mutants consequently remaining susceptible to e.g. cefepime-zidebactam or

485   meropenem-nacubactam at low concentrations (156, 157). Cefepime-zidebactam is currently

486   the most advanced of these combinations, with a phase 3 trial due to commence (160).

487

488   **Direct inhibitors of MBLs.**

489   **Cyclic boronates - VNRX-5133 (taniborbactam) and QPX7228**. Inhibitors that target both SBLs

490   and MBLs are of great interest but have proved difficult to obtain owing to structural and

491   functional differences between and among these enzymes. This combination of inhibitory

492   activities nonetheless has recently been achieved with several cyclic boronates, notably

493   taniborbactam and QPX7228. These mimic the tetrahedral anionic intermediate common to

494   SBL and MBL catalysis (161) and additionally inhibit some penicillin-binding proteins (e.g. PBP-

495   5, which is non-essential) by the same mechanism (162). They represent a considerable

496   expansion in spectrum over vaborbactam, their progenitor, which inhibits only few class A β-

497   lactamases, notably KPC types (163).

498   Taniborbactam (VenatoRx) is the more advanced of these two 'second-generation'

499   boronates, and is in Phase III trials combined with cefepime (164). It irreversibly inhibits class

500   A, C, and D SBLs, and is a reversible competitive inhibitor of VIM and NDM MBLs, though not

501   of IMP types (165). Safety has been established in healthy volunteers (NCT02955459), and the

502   FDA has allowed cefepime-taniborbactam to proceed via fast track pathway for the clinical

503   indications of cUTI and cIAI.   QPX7728 (QPEX) likewise inhibits both SBLs and MBLs: 50%

504   inhibitory concentrations [IC_{50}], for KPC enzymes are around 2.9 ± 0.4 nM, compared with 22

505   ± 8 nM for the class C cephalosporinase of *E. cloacae* P99, 55 ± 25 nM for the NDM-1 MBL and

506   14 ± 4 nM for VIM-1 enzyme. As with taniborbactam, the IC_{50} for IMP-1 enzyme is considerably

507   higher, at 610 ± 70 nM) (166). An IV combination of QPX7728 with meropenem is being

508   explored. This significantly lowered bacterial counts in murine thigh and lung infection models

509   with carbapenem-resistant *K. pneumoniae*, *P. aeruginosa* and *A. baumannii* when compared

510   to meropenem alone, although strain genotypes were not reported. Unlike taniborbactam,

511　QPX7228 is orally bioavailable and combinations with ceftibuten and tebipenem were

512　evaluated *in vitro* against CPE, including those with MBLs (167).

513

514　**Thiol-containing MBL inhibitors and chelating agents**.　Small molecules that bind and/or

515　chelate zinc ions include thiols, dicarboxylates, hydroxamates, and tetrazoles; these are widely

516　reported to inhibit MBLs, but human metallo-proteases are vulnerable too, so toxicity may

517　preclude clinical development.

518　　　Thiol-containing compounds inhibit all MBL subtypes (B1, B2 and B3) (168), with strong

519　competitive inhibition of IMP-1 by thioester derivatives first reported in 1999 (169). The

520　dipeptide L-captopril deserves mention in context. It is used as an ACE inhibitor in the

521　treatment of hypertension and is reported also to inhibit MBLs by chelating the active site zinc

522　ions via its thiol group (170); the corresponding D- stereoisomer is a more potent inhibitor and

523　can potentiate meropenem against strains with VIM-2 MBLs (170). Both captopril isomers act

524　via zinc chelation and repurposing is attractive given the known safety of the L-isomer at its

525　licensed dose; however the economic model for development is yet to be established and

526　safety issues for the D-isomer need exploration. Other thio-carbonyl compounds, such as

527　thiomandelic acid, exhibit synergy with meropenem against Enterobacterales with VIM, NDM,

528　and IMP enzymes (171).

529　　　Bisthiazolidines are carboxylate-containing bicyclic compounds, considered to be

530　penicillin analogs that inhibit MBLs through a zinc-bridging thiol group and a carboxylate that

531　interacts with K224 (172). The orientation of the carboxylate and thiol moieties create diverse

532　binding that is observed on X-ray crystal structures and has been shown to inhibit all MBL types

533　(173). The bisthiazolidine scaffold inhibits NDM-1 enzymes *in vitro*, with K_i values in the low

534   micromolar range (from 7 ± 1 to 19 ±3 μM); they restore imipenem activity against *E. coli*

535   producing NDM-1 (172).

536   The divalent cation chelator EDTA has raised interest, too, both as an inhibitor of MBLs,

537   and also because it disrupts the gram-negative outer membrane and neutralizes various

538   bacterial enzymes and toxins (174, 175). It is widely used in identification tests for MBLs.

539   Sodium calcium EDTA, which is licensed for use for treatment of lead poisoning, reportedly

540   restored imipenem's activity *in vivo* against *P. aeruginosa* producing IMP- and VIM- enzymes

541   and against *E. coli* producing NDM-1 enzyme (176, 177), raising the issue of whether it might

542   be used to potentiate carbapenems in human infections. Elores®, which is marketed in India,

543   combines ceftriaxone, sulbactam and EDTA (178, 179) and reportedly achieved cures of

544   infections due to MBL producers in multiple patients, with no serious adverse events (178).

545   However, prospective and controlled studies are lacking, the dose of EDTA is low, and there

546   remains uncertainty (above) about the function of NDM-1 enzyme *in vivo*. More negatively,

547   the FDA has placed strict limits on the amount of EDTA permissible even in food (180) and

548   sodium calcium EDTA is capable of producing toxic effects that can be fatal (181). High

549   concentrations of EDTA are likely to strip divalent cations from human metalloenzymes,

550   including matrix metalloproteinases, carbonic anhydrase and carboxypeptidases, thus limiting

551   clinical applicability.

552   Aspergillomarasmine A (AMA) is a fungal natural product discovered in the 1960s (182),

553   and re-evaluated in the 1980s as an inhibitor of the human metalloproteinase angiotensin-

554   converting enzyme (ACE). AMA inhibits MBLs via a metal ion sequestration mechanism and

555   displays rapid and potent inhibition of NDM-1 and VIM-2 enzymes *in vitro* (183). It restored

556   the activity of meropenem against a *K. pneumoniae* strain expressing NDM-1 enzyme in an

557   intraperitoneal murine infection model (184). Again, the hazard of inhibiting human metallo-

558   enzymes requires careful investigation.

559

560   **Challenges for the development of inhibitors of MBLs**

561   One of the biggest challenges in designing MBL inhibitors is the diversity among these enzymes,

562   which share less than one third sequence identity at their active sites. Thus, for example,

563   taniborbactam and QPX7728 target NDM and VIM enzymes, but not IMP types (185).

564   Development of inhibitors that bind remotely from the active site might overcome this

565   limitation, but possible target areas also vary within class B1 and seem even better able to

566   tolerate mutations than the active site (29). Another challenge is the shallow binding site in B1

567   enzymes, meaning that inhibitors can only make limited interactions (29). Specificity for

568   bacterial MBLs is a further recurring challenge; interactions with human metallo-enzymes and

569   contingent toxicity are major concerns. Molecules that solely inhibit MBLs are limited by the

570   fact that many MBL producers also co-produce SBLs, including carbapenemases, meaning that

571   the partner β-lactam must evade these enzymes, that the inhibitor must inactivate both MBLs

572   and SBLs, or that a second inhibitor is required.

573   Preclinical development is challenging, too, because it is difficult to establish reliable

574   animal models in which MBL-mediated resistance is expressed, perhaps owing to the already-

575   mentioned lack of essential zinc at infection sites. Moreover bacteria are prone to lose MBL-

576   encoding plasmids, or fail to reliably express them, in murine models, resulting in

577   pharmacodynamic data that suggest meropenem susceptibility (186, 187). Consequently it is

578   difficult to establish the efficacy of candidate MBL-stable drugs or inhibitor combinations. It is

579   unclear if the same phenomena occur in patients (188), and this requires further research.

580   Irrespective of this aspect, it is also challenging to find and recruit the required number of

581   patients with MBL-producing pathogens to clinical trials. Rapid diagnostics should help, but

582   their use is complicated by cost and the need to deploy them to all trial sites, including in

583   countries where they are not licensed or are licensed only to inform infection control, not

584   treatment.

585

586   **Conclusion**

587   MBLs are disseminating internationally, particularly in Asia, and often are produced by gram-

588   negative bacteria with extremely broad spectra of *in vitro* resistance. Unlike for KPC and OXA-

589   48-like carbapenemases, producers are typically not susceptible to recently licensed β-

590   lactamase inhibitor combinations such as ceftazidime-avibactam, meropenem-vaborbactam,

591   imipenem-relebactam, although cefiderocol may be a potential answer. The ability of MBLs to

592   confer resistance to carbapenems may not be so great *in vivo* as *in vitro*, though this is

593   uncertain and may vary by enzyme type even within MBL subclasses.

594   Inhibitors are known, and the developmental boronates, taniborbactam and QPX7728

595   are of particular interest. Nonetheless, the quest for effective inhibitors is complicated by

596   differences in active site structure and zinc ligand interactions among MBLs, and by difficulties

597   in the design of appropriate preclinical and clinical trials. Non-boronate inhibitors face toxicity

598   issues, particularly if they interact with other metallo-enzymes or are general chelators. Other

599   approaches to overcoming MBLs include, avibactam-protected aztreonam; stable β-lactam,

600   notably BOS-228 as well as cefiderocol, and combinations of β-lactams with-triple action DBOs,

601   notably cefepime-zidebactam and meropenem-nacubactam.

602   And *that* is the positive aspect on which to close: there is now a diverse and exciting

603   pipeline of potential agents for the treatment of infections caused by bacteria that produce

604   MBLs. It remains to be seen what will be the most effective of these agents.

619

620

621 **References**

622 1. Walsh TR, Toleman MA, Poirel L, Nordmann P. 2005. Metallo-β-Lactamases: the Quiet

623   before the Storm? Clin Microbiol Rev 18:306–325.

624 2. World Health Organisation. 2015. Global Action Plan on Antimicrobial Resistance.

625   Geneva.

626 3. Salonen JH, Eerola E, Meurman O. 1998. Clinical significance and outcome of

627   anaerobic bacteremia. Clin Infect Dis 26:1413–7.

628 4. World Health Organisation. Kahlmeter G, Singh N. 2017. Global Priority List Of

629   Antibiotic-Resistant Bacteria To Guide Research, Discovery and Development of New

630   Antibiotics. Geneva

631   5.   Bush K, Jacoby GA. 2010. Updated functional classification of β-lactamases. Antimicrob

632   Agents Chemother 54:969–76.

633   6.   Hall BG, Barlow M. 2005. Revised Ambler classification of β-lactamases. J Antimicrob

634   Chemother 55:1050–1051.

635   7.   Garau G, García-Sáez I, Bebrone C, Anne C, Mercuri P, Galleni M, Frère J-M, Dideberg

636   O. 2004. Update of the standard numbering scheme for class B β-lactamases.

637   Antimicrob Agents Chemother 48:2347–9.

638   8.   Palzkill T. 2013. Metallo-β-lactamase structure and function. Ann N Y Acad Sci

639   1277:91–104.

640   9.   Marshall S, Hujer AM, Rojas LJ, Papp-Wallace KM, Humphries RM, Spellberg B, Hujer

641   KM, Marshall EK, Rudin SD, Perez F, Wilson BM, Wasserman RB, Chikowski L, Paterson

642   DL, Vila AJ, van Duin D, Kreiswirth BN, Chambers HF, Fowler VG, Jacobs MR, Pulse ME,

643   Weiss WJ, Bonomo RA, Bonomo RA. 2017. Can Ceftazidime-Avibactam and Aztreonam

644   Overcome β-Lactam Resistance Conferred by Metallo-β-Lactamases in

645   Enterobacteriaceae? Antimicrob Agents Chemother 61(4)pp:e02243-16.

646 10.   Watanabe M, Iyobe S, Inoue M, Mitsuhashi S. 1991. Transferable imipenem resistance

647   in *Pseudomonas aeruginosa*. Antimicrob Agents Chemother 35:147–51.

648 11.   Naas T, Oueslati S, Bonnin RA, Dabos ML, Zavala A, Dortet L, Retailleau P, Iorga BI.

649   2017. Beta-lactamase database (BLDB) – structure and function. J Enzyme Inhib Med

650   Chem 32:917–919.

651 12.   Lauretti L, Riccio ML, Mazzariol A, Cornaglia G, Amicosante G, Fontana R, Rossolini GM.

652   1999. Cloning and characterization of bla_{VIM}, a new integron-borne metallo-β-

653   lactamase gene from a *Pseudomonas aeruginosa* clinical isolate. Antimicrob Agents

654   Chemother 43:1584–90.

655   13.   Nordmann P, Naas T, Poirel L. 2011. Global spread of Carbapenemase-producing

656   Enterobacteriaceae. Emerg Infect Dis 17:1791–8.

657   14.   Brooke JS. 2012. *Stenotrophomonas maltophilia*: an emerging global opportunistic

658   pathogen. Clin Microbiol Rev 25:2–41.

659   15.   Denton M, Kerr KG. 1998. Microbiological and clinical aspects of infection associated

660   with *Stenotrophomonas maltophilia*. Clin Microbiol Rev 11:57–80.

661   16.   Akova M, Bonfiglio G, Livermore DM. 1991. Susceptibility to β-lactam antibiotics of

662   mutant strains of *Xanthomonas maltophilia* with high- and low-level constitutive

663   expression of L1 and L2 beta-lactamases. J Med Microbiol 35:208–213.

664   17.   González LJ, Vila AJ. 2012. Carbapenem resistance in *Elizabethkingia meningoseptica* is

665   mediated by metallo-β-lactamase BlaB. Antimicrob Agents Chemother 56:1686–92.

666   18.   Bennett PM. 2008. Plasmid encoded antibiotic resistance: acquisition and transfer of

667   antibiotic resistance genes in bacteria. Br J Pharmacol 153 Suppl 1:S347-57.

668   19.   Bonnin RA, Poirel L, Carattoli A, Nordmann P. 2012. Characterization of an IncFII

669   plasmid encoding NDM-1 from *Escherichia coli* ST131. PLoS One 7(4):e34752.

670   20.   Villa L, García-Fernández A, Fortini D, Carattoli A. 2010. Replicon sequence typing of

671   IncF plasmids carrying virulence and resistance determinants. J Antimicrob Chemother

672   65:2518–29.

673   21.   Rasheed JK, Kitchel B, Zhu W, Anderson KF, Clark NC, Ferraro MJ, Savard P, Humphries

674   RM, Kallen AJ, Limbago BM. 2013. New Delhi Metallo-β-Lactamase–producing

675   Enterobacteriaceae, United States. Emerg Infect Dis 19:870–878.

676   22.   Nithya N, Remitha R, Jayasree PR, Faisal M, Manish Kumar PR. 2017. Analysis of β-

677   lactamases, bla_{NDM-1} phylogeny and plasmid replicons in multidrug-resistant *Klebsiella*

678   spp. from a tertiary care centre in south India. Indian J Med Res 146:S38–S45.

679   23.   Wu W, Feng Y, Tang G, Qiao F, McNally A, Zong Z. 2019. NDM Metallo-β-Lactamases

680   and Their Bacterial Producers in Health Care Settings. Clin Microbiol Rev 32.

681   24.   Poirel L, Bonnin RA, Boulanger A, Schrenzel J, Kaase M, Nordmann P. 2012. Tn125-

682   related acquisition of bla_{NDM}-like genes in *Acinetobacter baumannii*. Antimicrob Agents

683   Chemother 56:1087–9.

684   25.   Joshi PR, Acharya M, Kakshapati T, Leungtongkam U, Thummeepak R, Sitthisak S. 2017.

685   Co-existence of bla_{OXA-23} and bla_{NDM-1} genes of *Acinetobacter baumannii* isolated from

686   Nepal: antimicrobial resistance and clinical significance. Antimicrob Resist Infect

687   Control 6:21.

688   26.   Zhou H, Guo W, Zhang J, Li Y, Zheng P, Zhang H. 2019. Draft genome sequence of a

689   metallo-β-lactamase (bla_{AIM-1})-producing *Klebsiella pneumoniae* ST1916 isolated from

690   a patient with chronic diarrhoea. J Glob Antimicrob Resist 16:165–167.

691   27.   Dabos L, Rodriguez CH, Nastro M, Dortet L, Bonnin RA, Famiglietti A, Iorga BI, Vay C,

692   Naas T. 2020. LMB-1 producing *Citrobacter freundii* from Argentina, a novel player in

693   the field of MBLs. Int J Antimicrob Agents 55:105857.

694   28.   Wachino J, Yoshida H, Yamane K, Suzuki S, Matsui M, Yamagishi T, Tsutsui A, Konda T,

695   Shibayama K, Arakawa Y. 2011. SMB-1, a novel subclass B3 metallo-β-lactamase,

696   associated with ISCR1 and a class 1 integron, from a carbapenem-resistant *Serratia*

697   *marcescens* clinical isolate. Antimicrob Agents Chemother 55:5143–9.

698   29.   Mojica MF, Bonomo RA, Fast W. 2016. B1-Metallo-β-Lactamases: Where Do We

699   Stand? Curr Drug Targets 17:1029–50.

700   30.   Brem J, Struwe WB, Rydzik AM, Tarhonskaya H, Pfeffer I, Flashman E, van Berkel SS,

701   Spencer J, Claridge TDW, McDonough MA, Benesch JLP, Schofield CJ. 2015. Studying

702   the active-site loop movement of the São Paolo metallo-β-lactamase-1. Chem Sci

703   6:956–963.

704   31.   Page MI, Badarau A. 2008. The mechanisms of catalysis by metallo-β-lactamases.

705   Bioinorg Chem Appl 2008:576297.

706   32.   Lisa M-N, Palacios AR, Aitha M, González MM, Moreno DM, Crowder MW, Bonomo

707   RA, Spencer J, Tierney DL, Llarrull LI, Vila AJ. 2017. A general reaction mechanism for

708   carbapenem hydrolysis by mononuclear and binuclear metallo-β-lactamases. Nat

709   Commun 8:538.

710   33.   Feng H, Liu X, Wang S, Fleming J, Wang D-C, Liu W. 2017. The mechanism of NDM-1-

711   catalyzed carbapenem hydrolysis is distinct from that of penicillin or cephalosporin

712   hydrolysis. Nat Commun 8:2242.

713   34.   Shen B, Yu Y, Chen H, Cao X, Lao X, Fang Y, Shi Y, Chen J, Zheng H. 2013. Inhibitor

714   Discovery of Full-Length New Delhi Metallo-β-Lactamase-1 (NDM-1). PLoS One

715   8:e62955.

716   35.   Livermore D, Mushtaq S, Warner M, Woodford N. 2015. Activity of OP0595/β-lactam

717   Combinations Against Gram-negative Bacteria With Extended-Spectrum, AmpC and

718   Carbapenem-Hydrolysing β-lactamases. J Antimicrob Chemother 70(11):3032-41.

719   36.   Walsh TR. 2005. The emergence and implications of metallo-β-lactamases in Gram-

720   negative bacteria. Clin Microbiol Infect 11:2–9.

721   37.   Makena A, Brem J, Pfeffer I, Geffen REJ, Wilkins SE, Tarhonskaya H, Flashman E, Phee

722   LM, Wareham DW, Schofield CJ. 2015. Biochemical characterization of New Delhi

723   metallo-β-lactamase variants reveals differences in protein stability. J Antimicrob

724   Chemother 70:463–469.

725   38.   Stewart AC, Bethel CR, VanPelt J, Bergstrom A, Cheng Z, Miller CG, Williams C, Poth R,

726   Morris M, Lahey O, Nix JC, Tierney DL, Page RC, Crowder MW, Bonomo RA, Fast W.

727   2017. Clinical Variants of New Delhi Metallo-β-Lactamase Are Evolving To Overcome

728   Zinc Scarcity. ACS Infect Dis 3:927–940.

729   39.   Bahr G, Vitor-Horen L, Bethel CR, Bonomo RA, González LJ, Vila AJ. 2018. Clinical

730   Evolution of New Delhi Metallo-β-Lactamase (NDM) Optimizes Resistance under Zn(II)

731   Deprivation. Antimicrob Agents Chemother 62(1):e01849-17.

732   40.   Corbin BD, Seeley EH, Raab A, Feldmann J, Miller MR, Torres VJ, Anderson KL, Dattilo

733   BM, Dunman PM, Gerads R, Caprioli RM, Nacken W, Chazin WJ, Skaar EP. 2008. Metal

734   chelation and inhibition of bacterial growth in tissue abscesses. Science 319:962–5.

735   41.   Cheng Z, Thomas PW, Ju L, Bergstrom A, Mason K, Clayton D, Miller C, Bethel CR,

736   VanPelt J, Tierney DL, Page RC, Bonomo RA, Fast W, Crowder MW. 2018. Evolution of

737   New Delhi metallo-β-lactamase (NDM) in the clinic: Effects of NDM mutations on

738   stability, zinc affinity, and mono-zinc activity. J Biol Chem 293:12606–12618.

739   42.   Ahammad ZS, Sreekrishnan TR, Hands CL, Knapp CW, Graham DW. 2014. Increased

740   waterborne bla_{NDM-1} resistance gene abundances associated with seasonal human

741   pilgrimages to the upper ganges river. Environ Sci Technol 48:3014–3020.

742   43.   van Duin D, Doi Y. 2017. The global epidemiology of carbapenemase-producing

743   Enterobacteriaceae. Virulence 8:460–469.

744   44.   Yong D, Toleman MA, Giske CG, Cho HS, Sundman K, Lee K, Walsh TR. 2009.

745   Characterization of a new metallo-β-lactamase gene, bla_{NDM-1}, and a novel

746   erythromycin esterase gene carried on a unique genetic structure in Klebsiella

747   pneumoniae sequence type 14 from India. Antimicrob Agents Chemother 53:5046–54.

748   45.   Woodford N, Johnson AP. 2013. Global spread of antibiotic resistance: the example of

749   New Delhi metallo-β-lactamase (NDM)-mediated carbapenem resistance. J Med

750   Microbiol 62:499–513.

751   46.   Kumarasamy KK, Toleman MA, Walsh TR, Bagaria J, Butt F, Balakrishnan R, Chaudhary

752   U, Doumith M, Giske CG, Irfan S, Krishnan P, Kumar A V, Maharjan S, Mushtaq S,

753   Noorie T, Paterson DL, Pearson A, Perry C, Pike R, Rao B, Ray U, Sarma JB, Sharma M,

754   Sheridan E, Thirunarayan MA, Turton J, Upadhyay S, Warner M, Welfare W, Livermore

755   DM, Woodford N. 2010. Emergence of a new antibiotic resistance mechanism in India,

756   Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect

757   Dis 10:597–602.

758   47.   Heinz E, Ejaz H, Bartholdson Scott J, Wang N, Gujaran S, Pickard D, Wilksch J, Cao H,

759   Haq I-U, Dougan G, Strugnell RA. 2019. Resistance mechanisms and population

760   structure of highly drug resistant *Klebsiella* in Pakistan during the introduction of the

761   carbapenemase NDM-1. Sci Rep 9:2392.

762   48.   Castanheira M, Deshpande LM, Mathai D, Bell JM, Jones RN, Mendes RE. 2011. Early

763   dissemination of NDM-1- and OXA-181-producing Enterobacteriaceae in Indian

764   hospitals: report from the SENTRY Antimicrobial Surveillance Program, 2006-2007.

765   Antimicrob Agents Chemother 55:1274–8.

766   49.   Walsh TR, Weeks J, Livermore DM, Toleman MA. 2011. Dissemination of NDM-1

767   positive bacteria in the New Delhi environment and its implications for human health:

768   an environmental point prevalence study. Lancet Infect Dis 11:355–362.

769   50.   Kazi M, Drego L, Nikam C, Ajbani K, Soman R, Shetty A, Rodrigues C. 2015. Molecular

770   characterization of carbapenem-resistant Enterobacteriaceae at a tertiary care

771   laboratory in Mumbai. Eur J Clin Microbiol Infect Dis 34:467–472.

772   51.   Garg A, Garg J, Kumar S, Bhattacharya A, Agarwal S, Upadhyay G. 2019. Molecular

773   epidemiology and therapeutic options of carbapenem-resistant Gram-negative

774   bacteria. Indian J Med Res 149:285.

775   52.   Zhang R, Liu L, Zhou H, Chan EW, Li J, Fang Y, Li Y, Liao K, Chen S. 2017. Nationwide

776   Surveillance of Clinical Carbapenem-resistant Enterobacteriaceae (CRE) Strains in

777   China. EBioMedicine 19:98–106.

778   53.   Cai Y, Chen C, Zhao M, Yu X, Lan K, Liao K, Guo P, Zhang W, Ma X, He Y, Zeng J, Chen L,

779   Jia W, Tang Y-W, Huang B. 2019. High Prevalence of Metallo-β-Lactamase-Producing

780   *Enterobacter cloacae* From Three Tertiary Hospitals in China. Front Microbiol 10:1610.

781   54.   Wang Y, Lo W-U, Lai RW-M, Tse CW-S, Lee RA, Luk W-K, Cheng VC-C, Que T-L, Chow K-

782   H, Ho P-L. 2017. IncN ST7 epidemic plasmid carrying bla_{IMP-4} in Enterobacteriaceae

783   isolates with epidemiological links to multiple geographical areas in China. J Antimicrob

784   Chemother 72:99–103.

785   55.   Dong F, Lu J, Wang Y, Shi J, Zhen JH, Chu P, Zhen Y, Han SJ, Guo YL, Song WQ. 2017. A

786   Five-year Surveillance of Carbapenemase-producing *Klebsiella pneumoniae* in a

787   Pediatric Hospital in China Reveals Increased Predominance of NDM-1. Biomed

788   Environ Sci 30:562–569.

789   56.   Du H, Chen L, Tang Y-W, Kreiswirth BN. 2016. Carbapenem-resistant and colistin-

790   resistant *Escherichia coli* co-producing NDM-9 and MCR-1. Lancet Infect Dis 16:288–

791   289.

792   57.   Lutgring JD, Limbago BM. 2016. The Problem of Carbapenemase-Producing-

793   Carbapenem-Resistant-Enterobacteriaceae Detection. J Clin Microbiol 54:529–34.

794   58.   Al-Agamy MH, Aljallal A, Radwan HH, Shibl AM. 2018. Characterization of

795   carbapenemases, ESBLs, and plasmid-mediated quinolone determinants in

796   carbapenem-insensitive *Escherichia coli* and *Klebsiella pneumoniae* in Riyadh hospitals.

34

797   J Infect Public Health 11:64–68.

798   59.   Zowawi HM, Sartor AL, Balkhy HH, Walsh TR, Al Johani SM, AlJindan RY, Alfaresi M,

799   Ibrahim E, Al-Jardani A, Al-Abri S, Al Salman J, Dashti AA, Kutbi AH, Schlebusch S,

800   Sidjabat HE, Paterson DL. 2014. Molecular characterization of carbapenemase-

801   producing *Escherichia coli* and *Klebsiella pneumoniae* in the countries of the Gulf

802   cooperation council: dominance of OXA-48 and NDM producers. Antimicrob Agents

803   Chemother 58:3085–90.

804   60.   Zowawi HM, Syrmis MW, Kidd TJ, Balkhy HH, Walsh TR, Al Johani SM, Al Jindan RY,

805   Alfaresi M, Ibrahim E, Al-Jardani A, Al Salman J, Dashti AA, Sidjabat HE, Baz O,

806   Trembizki E, Whiley DM, Paterson DL. 2018. Identification of carbapenem-resistant

807   *Pseudomonas aeruginosa* in selected hospitals of the Gulf Cooperation Council States:

808   dominance of high-risk clones in the region. J Med Microbiol 67:846–853.

809   61.   Ayoub Moubareck C, Hammoudi Halat D, Akkawi C, Nabi A, AlSharhan MA, AlDeesi ZO,

810   Peters CC, Celiloglu H, Karam Sarkis D. 2019. Role of outer membrane permeability,

811   efflux mechanism, and carbapenemases in carbapenem-nonsusceptible *Pseudomonas*

812   *aeruginosa* from Dubai hospitals: Results of the first cross-sectional survey. Int J Infect

813   Dis 84:143–150.

814   62.   Edelstein M V, Skleenova EN, Shevchenko O V, D'souza JW, Tapalski D V, Azizov IS,

815   Sukhorukova M V, Pavlukov RA, Kozlov RS, Toleman MA, Walsh TR. 2013. Spread of

816   extensively resistant VIM-2-positive ST235 *Pseudomonas aeruginosa* in Belarus,

817   Kazakhstan, and Russia: a longitudinal epidemiological and clinical study. Lancet Infect

818   Dis 13:867–876.

819   63.   Ageevets VA, Partina I V, Lisitsyna ES, Ilina EN, Lobzin Y V, Shlyapnikov SA, Sidorenko S

820   V. 2014. Emergence of carbapenemase-producing Gram-negative bacteria in Saint

821   Petersburg, Russia. Int J Antimicrob Agents 44:152–5.

822   64.   Lazareva I V, Ageevets VA, Ershova TA, Zueva LP, Goncharov AE, Darina MG,

823   Svetlichnaya YS, Uskov AN, Sidorenko S V. 2016. Prevalence and Antibiotic Resistance

824   of Carbapenemase-Producing Gram-Negative Bacteria in Saint Petersburg and Some

825   Other Regions of the Russian Federation. Antibiot khimioter 61(11-12):28–38.

826   65.   Fursova NK, Astashkin EI, Knyazeva AI, Kartsev NN, Leonova ES, Ershova ON,

827   Alexandrova IA, Kurdyumova N V, Sazikina SY, Volozhantsev N V, Svetoch EA, Dyatlov

828   IA. 2015. The spread of bla_{OXA-48} and $bla_{OXA-244}$ carbapenemase genes among *Klebsiella*

829   *pneumoniae*, *Proteus mirabilis* and *Enterobacter* spp. isolated in Moscow, Russia. Ann

830   Clin Microbiol Antimicrob 14:46.

831   66.   Luzzaro F, Docquier J-D, Colinon C, Endimiani A, Lombardi G, Amicosante G, Rossolini

832   GM, Toniolo A. 2004. Emergence in *Klebsiella pneumoniae* and *Enterobacter cloacae*

833   clinical isolates of the VIM-4 metallo-β-lactamase encoded by a conjugative plasmid.

834   Antimicrob Agents Chemother 48:648–50.

835   67.   Hasan CM, Turlej-Rogacka A, Vatopoulos AC, Giakkoupi P, Maâtallah M, Giske CG.

836   2014. Dissemination of bla_{VIM} in Greece at the peak of the epidemic of 2005–2006:

837   clonal expansion of *Klebsiella pneumoniae* clonal complex 147. Clin Microbiol Infect

838   20:34–37.

839   68.   Vatopoulos A. 2008. High rates of metallo-β-lactamase-producing *Klebsiella*

840   *pneumoniae* in Greece - a review of the current evidence. Euro Surveill 13.

841   69.   Giakkoupi P, Maltezou H, Polemis M, Pappa O, Saroglou G, Vatopoulos A, the Greek

842   System for the Surveillan C. 2009. KPC-2-producing *Klebsiella pneumoniae* infections in

843   Greek hospitals are mainly due to a hyperepidemic clone. Eurosurveillance 14.

844   70.   Papadimitriou-Olivgeris M, Bartzavali C, Lambropoulou A, Solomou A, Tsiata E,

845   Anastassiou ED, Fligou F, Marangos M, Spiliopoulou I, Christofidou M. 2019. Reversal

846   of carbapenemase-producing *Klebsiella pneumoniae* epidemiology from bla_{KPC} to

847   bla_{VIM} harbouring isolates in a Greek ICU after introduction of ceftazidime/avibactam. J

848   Antimicrob Chemother 74:2051–2054.

849   71.   Public Health England. 2017. English surveillance programme for antimicrobial

850   utilisation and resistance (ESPAUR) Report 2017. London

851   72.   Wright LL, Turton JF, Livermore DM, Hopkins KL, Woodford N. 2015. Dominance of

852   international "high-risk clones" among metallo-β-lactamase-producing *Pseudomonas*

853   *aeruginosa* in the UK. J Antimicrob Chemother 70:103–10.

854   73.   Public Health England. 2018. English Surveillance Programme for Antimicrobial

855   Utilisation and Resistance (ESPAUR).

856   74.   Albiger B, Glasner C, Struelens MJ, Grundmann H, Monnet DL, European Survey of

857   Carbapenemase-Producing Enterobacteriaceae (EuSCAPE) working group. 2015.

858   Carbapenemase-producing Enterobacteriaceae in Europe: assessment by national

859   experts from 38 countries, May 2015. Eurosurveillance 20:30062.

860   75.   Grundmann H, Glasner C, Albiger B, Aanensen DM, Tomlinson CT, Andrasević AT,

861   Cantón R, Carmeli Y, Friedrich AW, Giske CG, Glupczynski Y, Gniadkowski M, Livermore

862   DM, Nordmann P, Poirel L, Rossolini GM, Seifert H, Vatopoulos A, Walsh T, Woodford

863   N, Monnet DL, Koraqi A, Lacej D, Apfalter P, Hartl R, Glupczynski Y, Huang T-D, Strateva

864   T, Marteva-Proevska Y, Andrasevic AT, Butic I, Pieridou-Bagatzouni D, Maikanti-

865   Charalampous P, Hrabak J, Zemlickova H, Hammerum A, Jakobsen L, Ivanova M,

866   Pavelkovich A, Jalava J, Österblad M, Dortet L, Vaux S, Kaase M, Gatermann SG,

867   Vatopoulos A, Tryfinopoulou K, Tóth Á, Jánvári L, Boo TW, McGrath E, Carmeli Y, Adler

868   A, Pantosti A, Monaco M, Raka L, Kurti A, Balode A, Saule M, Miciuleviciene J,

869 Mierauskaite A, Perrin-Weniger M, Reichert P, Nestorova N, Debattista S, Mijovic G,

870 Lopicic M, Samuelsen Ø, Haldorsen B, Zabicka D, Literacka E, Caniça M, Manageiro V,

871 Kaftandzieva A, Trajkovska-Dokic E, Damian M, Lixandru B, Jelesic Z, Trudic A, Niks M,

872 Schreterova E, Pirs M, Cerar T, Oteo J, Aracil B, Giske C, Sjöström K, Gür D, Cakar A,

873 Woodford N, Hopkins K, Wiuff C, Brown DJ. 2017. Occurrence of carbapenemase-

874 producing *Klebsiella pneumoniae* and *Escherichia coli* in the European survey of

875 carbapenemase-producing Enterobacteriaceae (EuSCAPE): a prospective,

876 multinational study. Lancet Infect Dis 17:153–163.

877 76. Livermore DM, Walsh TR, Toleman M, Woodford N. 2011. Balkan NDM-1: escape or

878 transplant? Lancet Infect Dis 11:164.

879 77. Little ML, Qin X, Zerr DM, Weissman SJ. 2012. Molecular diversity in mechanisms of

880 carbapenem resistance in paediatric Enterobacteriaceae. Int J Antimicrob Agents

881 39:52–57.

882 78. Centers for Disease Control and Prevention (CDC). 2010. Detection of

883 Enterobacteriaceae isolates carrying metallo-beta-lactamase - United States, 2010.

884 MMWR Morb Mortal Wkly Rep 59:750.

885 79. Centers for Disease Control and Prevention (CDC).2013. Notes from the Field: New

886 Delhi Metallo-β-Lactamase–Producing Escherichia coli Associated with Endoscopic

887 Retrograde Cholangiopancreatography — Illinois.

888 80. Canadian Public Health Laboratory Network (CPHLN). 2017. CPHLN Voluntary

889 Reporting of Carbapenemase-Producing Enterobacteriaeceae 2008-2017.

890 81. Kohler PP, Melano RG, Patel SN, Shafinaz S, Faheem A, Coleman BL, Green K,

891 Armstrong I, Almohri H, Borgia S, Borgundvaag E, Johnstone J, Katz K, Lam F, Muller

892 MP, Powis J, Poutanen SM, Richardson D, Rebbapragada A, Sarabia A, Simor A, McGeer

893   A, Toronto Invasive Bacterial Diseases Network (TIBDN). 2018. Emergence of

894   Carbapenemase-Producing Enterobacteriaceae , South-Central Ontario, Canada1.

895   Emerg Infect Dis 24:1674–1682.

896   82.   Boyd DA, Lisboa LF, Rennie R, Zhanel GG, Dingle TC, Mulvey MR. 2019. Identification of

897   a novel metallo-β-lactamase, CAM-1, in clinical *Pseudomonas aeruginosa* isolates from

898   Canada. J Antimicrob Chemother 74:1563–1567.

899   83.   Kazmierczak KM, Rabine S, Hackel M, McLaughlin RE, Biedenbach DJ, Bouchillon SK,

900   Sahm DF, Bradford PA. 2016. Multiyear, Multinational Survey of the Incidence and

901   Global Distribution of Metallo-β-Lactamase-Producing Enterobacteriaceae and

902   *Pseudomonas aeruginosa*. Antimicrob Agents Chemother 60:1067–1078.

903   84.   Manenzhe RI, Zar HJ, Nicol MP, Kaba M. 2015. The spread of carbapenemase-

904   producing bacteria in Africa: a systematic review. J Antimicrob Chemother 70:23–40.

905   85.   Rubin JE, Peirano G, Peer AK, Govind CN, Pitout JDD. 2014. NDM-1–producing

906   Enterobacteriaceae from South Africa: moving towards endemicity? Diagn Microbiol

907   Infect Dis 79:378–380.

908   86.   Brinkac LM, White R, D'Souza R, Nguyen K, Obaro SK, Fouts DE. 2019. Emergence of

909   New Delhi Metallo-β-Lactamase (NDM-5) in *Klebsiella quasipneumoniae* from

910   Neonates in a Nigerian Hospital. mSphere 4:e00685-18.

911   87.   African Patients Dominate Indias Medical Tourism - Medical Tourism.

912   https://oisservices.com/medicaltourism/blog/african-patients-dominate-indias-

913   medical-tourism/ (accessed 9th February 2020)

914   88.   da Silva IR, Aires CAM, Conceição-Neto OC, de Oliveira Santos IC, Ferreira Pereira N,

915   Moreno Senna JP, Carvalho-Assef APD, Asensi MD, Rocha-de-Souza CM. 2019.

916   Distribution of Clinical NDM-1-Producing Gram-Negative Bacteria in Brazil. Microb

917   Drug Resist 25:394–399.

918   89.   Zurita J, Parra H, Gestal MC, McDermott J, Barba P. 2015. First case of NDM-1-

919   producing *Providencia rettgeri* in Ecuador. J Glob Antimicrob Resist 3:302–303.

920   90.   Saavedra-Rojas S-Y, Duarte-Valderrama C, González-de-Arias M-N, Ovalle-Guerro MV.

921   2017. Emergence of *Providencia rettgeri* NDM-1 in two departments of Colombia,

922   2012-2013. Enferm Infecc Microbiol Clin 35:354–358.

923   91.   Gales AC, Menezes LC, Silbert S, Sader HS. 2003. Dissemination in distinct Brazilian

924   regions of an epidemic carbapenem-resistant *Pseudomonas aeruginosa* producing

925   SPM metallo-β-lactamase. J Antimicrob Chemother 52:699–702.

926   92.   Zavascki AP, Barth AL, Gonçalves ALS, Moro ALD, Fernandes JF, Martins AF, Ramos F,

927   Goldani LZ. 2006. The influence of metallo-β-lactamase production on mortality in

928   nosocomial *Pseudomonas aeruginosa* infections. J Antimicrob Chemother 58:387–92.

929   93.   Sidjabat HE, Townell N, Nimmo GR, George NM, Robson J, Vohra R, Davis L, Heney C,

930   Paterson DL. 2015. Dominance of IMP-4-producing *Enterobacter cloacae* among

931   carbapenemase-producing Enterobacteriaceae in Australia. Antimicrob Agents

932   Chemother 59:4059–66.

933   94.   Roberts LW, Catchpoole E, Jennison A V, Bergh H, Hume A, Heney C, George N,

934   Paterson DL, Schembri MA, Beatson SA, Harris PNA. 2019. Genomic analysis of

935   carbapenemase-producing Enterobacteriaceae in Queensland reveals widespread

936   transmission of bla_{IMP-4} on an IncHI2 plasmid. Microb genom 6(1):e000321

937   95.   Abraham S, O'Dea M, Trott DJ, Abraham RJ, Hughes D, Pang S, McKew G, Cheong EYL,

938   Merlino J, Saputra S, Malik R, Gottlieb T. 2016. Isolation and plasmid characterization

939   of carbapenemase (IMP-4) producing *Salmonella enterica* Typhimurium from cats. Sci

940   Rep 6:35527.

941   96.   Dolejska M, Masarikova M, Dobiasova H, Jamborova I, Karpiskova R, Havlicek M, Carlile

942   N, Priddel D, Cizek A, Literak I. 2016. High prevalence of *Salmonella* and IMP-4-

943   producing Enterobacteriaceae in the silver gull on Five Islands, Australia. J Antimicrob

944   Chemother 71:63–70.

945   97.   Lim HM, Pène JJ, Shaw RW. 1988. Cloning, nucleotide sequence, and expression of the

946   *Bacillus cereus* 5/B/6 β-lactamase II structural gene. J Bacteriol 170:2873–8.

947   98.   Kuwabara S, Abraham EP. 1967. Some properties of two extracellular β-lactamases

948   from *Bacillus cereus* 569/H. Biochem J 103:27C-30C.

949   99.   Hawkey PM, Warren RE, Livermore DM, McNulty CAM, Enoch DA, Otter JA, Wilson

950   APR. 2018. Treatment of infections caused by multidrug-resistant Gram-negative

951   bacteria: report of the British Society for Antimicrobial Chemotherapy/Healthcare

952   Infection Society/British Infection Association Joint Working Party. J Antimicrob

953   Chemother 73:iii2–iii78.

954   100.   Jeon YD, Jeong WY, Kim MH, Jung IY, Ahn MY, Ann HW, Ahn JY, Han SH, Choi JY, Song

955   YG, Kim JM, Ku NS. 2016. Risk factors for mortality in patients with *Stenotrophomonas*

956   *maltophilia* bacteremia. Medicine (Baltimore) 95:e4375.

957   101.   Senol E, DesJardin J, Stark PC, Barefoot L, Snydman DR. 2002. Attributable Mortality of

958   *Stenotrophomonas maltophilia* Bacteremia. Clin Infect Dis 34:1653–1656.

959   102.   Asempa TE, Abdelraouf K, Nicolau DP. 2020. Metallo-β-lactamase resistance in

960   Enterobacteriaceae is an artefact of currently utilized antimicrobial susceptibility

961   testing methods. J Antimicrob Chemother 75:997–1005.

962   103.   Gammoh NZ, Rink L. 2017. Zinc in Infection and Inflammation. Nutrients 9(6):624.

963   104.   González LJ, Bahr G, Nakashige TG, Nolan EM, Bonomo RA, Vila AJ. 2016. Membrane

964   anchoring stabilizes and favors secretion of New Delhi metallo-β-lactamase. Nat Chem

965   Biol 12:516–22.

966   105.   Monogue ML, Abbo LM, Rosa R, Camargo JF, Martinez O, Bonomo RA, Nicolau DP.

967   2017. *In Vitro* Discordance with *In Vivo* Activity: Humanized Exposures of Ceftazidime-

968   Avibactam, Aztreonam, and Tigecycline Alone and in Combination against New Delhi

969   Metallo-β-Lactamase-Producing *Klebsiella pneumoniae* in a Murine Lung Infection

970   Model. Antimicrob Agents Chemother 61:e00486-17

971   106.   Chibabhai V, Nana T, Bosman N, Thomas T, Lowman W. 2018. Were all

972   carbapenemases created equal? Treatment of NDM-producing extensively drug-

973   resistant Enterobacteriaceae: a case report and literature review. Infection 46:1–13.

974   107.   Naim H, Rizvi M, Azam M, Gupta R, Taneja N, Shukla I, Khan H. 2017. Alarming

975   emergence, molecular characterization, and outcome of bla_{NDM-1} in patients infected

976   with multidrug-resistant Gram-negative bacilli in a tertiary care hospital. J Lab

977   Physicians 9:170.

978   108.   Datta S, Roy S, Chatterjee S, Saha A, Sen B, Pal T, Som T, Basu S. 2014. A Five-Year

979   Experience of Carbapenem Resistance in Enterobacteriaceae Causing Neonatal

980   Septicaemia: Predominance of NDM-1. PLoS One 9:e112101.

981   109.   de Jager P, Chirwa T, Naidoo S, Perovic O, Thomas J. 2015. Nosocomial Outbreak of

982   New Delhi Metallo-β-Lactamase-1-Producing Gram-Negative Bacteria in South Africa:

983   A Case-Control Study. PLoS One 10:e0123337.

984   110.   Freire MP, Abdala E, Moura ML, de Paula FJ, Spadão F, Caiaffa-Filho HH, David-Neto E,

985   Nahas WC, Pierrotti LC. 2015. Risk factors and outcome of infections with *Klebsiella*

986   *pneumoniae* carbapenemase-producing *K. pneumoniae* in kidney transplant recipients.

987   Infection 43:315–23.

988   111.   Fraenkel-Wandel Y, Raveh-Brawer D, Wiener-Well Y, Yinnon AM, Assous M V. 2016.

989   Mortality due to *bla*_{KPC} Klebsiella pneumoniae bacteraemia. J Antimicrob Chemother

990   71:1083–7.

991   112.   Mathur P, Sagar S, Kumar S, Sharma V, Gupta D, Lalwani S, Rani R, Muruganantham A.

992   2016. Does the presence of *Klebsiella pneumoniae* carbapenemase and New Delhi

993   metallo-β-lactamase-1 genes in pathogens lead to fatal outcome? Indian J Med

994   Microbiol 34:495–499.

995   113.   van Duin D, Kaye KS, Neuner EA, Bonomo RA. 2013. Carbapenem-resistant

996   Enterobacteriaceae: a review of treatment and outcomes. Diagn Microbiol Infect Dis

997   75:115–120.

998   114.   Daikos GL, Petrikkos P, Psichogiou M, Kosmidis C, Vryonis E, Skoutelis A, Georgousi K,

999   Tzouvelekis LS, Tassios PT, Bamia C, Petrikkos G. 2009. Prospective observational study

1000   of the impact of VIM-1 metallo-β-lactamase on the outcome of patients with *Klebsiella*

1001   *pneumoniae* bloodstream infections. Antimicrob Agents Chemother 53:1868–73.

1002 115.   Daikos GL, Kosmidis C, Tassios PT, Petrikkos G, Vasilakopoulou A, Psychogiou M,

1003   Stefanou I, Avlami A, Katsilambros N. 2007. Enterobacteriaceae Bloodstream

1004   Infections: Presence of Integrons, Risk Factors, and Outcome. Antimicrob Agents

1005   Chemother 51:2366–2372.

1006 116.   Huang S, Dai W, Sun S, Zhang X, Zhang L. 2012. Prevalence of Plasmid-Mediated

1007   Quinolone Resistance and Aminoglycoside Resistance Determinants among

1008   Carbapeneme Non-Susceptible *Enterobacter cloacae*. PLoS One 7:e47636.

1009 117.   Rodríguez-Baño J, Gutiérrez-Gutiérrez B, Machuca I, Pascual A. 2018. Treatment of

1010   Infections Caused by Extended-Spectrum-β-Lactamase-, AmpC-, and Carbapenemase-

1011   Producing Enterobacteriaceae. Clin Microbiol Rev 31(2):e00079-17.

1012 118.   Gutiérrez-Gutiérrez B, Salamanca E, de Cueto M, Hsueh P-R, Viale P, Paño-Pardo JR,

1013   Venditti M, Tumbarello M, Daikos G, Cantón R, Doi Y, Tuon FF, Karaiskos I, Pérez-

1014   Nadales E, Schwaber MJ, Azap ÖK, Souli M, Roilides E, Pournaras S, Akova M, Pérez F,

1015   Bermejo J, Oliver A, Almela M, Lowman W, Almirante B, Bonomo RA, Carmeli Y,

1016   Paterson DL, Pascual A, Rodríguez-Baño J, del Toro MD, Gálvez J, Falcone M, Russo A,

1017   Giamarellou H, Trecarichi EM, Losito AR, García-Vázquez E, Hernández A, Gómez J, Bou

1018   G, Iosifidis E, Prim N, Navarro F, Mirelis B, Skiada A, Origüen J, Juan RS, Fernández-Ruiz

1019   M, Larrosa N, Puig-Asensio M, Cisneros JM, Molina J, González V, Rucci V, de Gopegui

1020   ER, Marinescu CI, Martínez-Martínez L, Fariñas MC, Cano ME, Gozalo M, Mora-Rillo M,

1021   Francisco CN-S, Peña C, Gómez-Zorrilla S, Tubau F, Tsakris A, Zarkotou O, Antoniadou

1022   A, Poulakou G, Pitout J, Virmani D, Torre-Cisneros J, Guzmán-Puche J, Helvaci Ö, Sahin

1023   AO, Pintado V, Ruiz P, Bartoletti M, Giannella M, Tacconelli E, Riemenschneider F,

1024   Calbo E, Badia C, Xercavins M, Gasch O, Fontanals D, Jové E. 2017. Effect of

1025   appropriate combination therapy on mortality of patients with bloodstream infections

1026   due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective

1027   cohort study. Lancet Infect Dis.

1028   119.   Daikos GL, Tsaousi S, Tzouvelekis LS, Anyfantis I, Psichogiou M, Argyropoulou A,

1029   Stefanou I, Sypsa V, Miriagou V, Nepka M, Georgiadou S, Markogiannakis A, Goukos D,

1030   Skoutelis A. 2014. Carbapenemase-producing *Klebsiella pneumoniae* bloodstream

1031   infections: lowering mortality by antibiotic combination schemes and the role of

1032   carbapenems. Antimicrob Agents Chemother 58:2322–8.

1033   120.   van Duin D, Lok JJ, Earley M, Cober E, Richter SS, Perez F, Salata RA, Kalayjian RC,

1034   Watkins RR, Doi Y, Kaye KS, Fowler VG, Paterson DL, Bonomo RA, Evans S, Antibacterial

1035   Resistance Leadership Group. 2018. Colistin Versus Ceftazidime-Avibactam in the

1036   Treatment of Infections Due to Carbapenem-Resistant Enterobacteriaceae. Clin Infect

1037   Dis 66:163–171.

1038   121.   Otter JA, Doumith M, Davies F, Mookerjee S, Dyakova E, Gilchrist M, Brannigan ET,

1039   Bamford K, Galletly T, Donaldson H, Aanensen DM, Ellington MJ, Hill R, Turton JF,

1040   Hopkins KL, Woodford N, Holmes A. 2017. Emergence and clonal spread of colistin

1041   resistance due to multiple mutational mechanisms in carbapenemase-producing

1042   *Klebsiella pneumoniae* in London. Sci Rep 7:12711.

1043   122.   Kanwar A, Marshall SH, Perez F, Tomas M, Jacobs MR, Hujer AM, Domitrovic TN, Rudin

1044   SD, Rojas LJ, Kreiswirth BN, Chen L, Quinones-Mateu M, van Duin D, Bonomo RA. 2018.

1045   Emergence of Resistance to Colistin During the Treatment of Bloodstream Infection

1046   Caused by *Klebsiella pneumoniae* Carbapenemase–Producing *Klebsiella pneumoniae*.

1047   Open Forum Infect Dis 5(4):ofy054.

1048   123.   Lutgring JD, Balbuena R, Reese N, Gilbert SE, Ansari U, Bhatnagar A, Boyd S, Campbell

1049   D, Cochran J, Haynie J, Ilutsik J, Longo C, Swint S, Rasheed JK, Brown AC, Karlsson M.

1050   2020. Antibiotic Susceptibility of NDM-Producing Enterobacterales Collected in the

1051   United States, 2017–2018. Antimicrob Agents Chemother Jun 15.

1052   124.   Livermore DM, Mushtaq S, Warner M, Woodford N. 2016. In Vitro Activity of

1053   Eravacycline against Carbapenem-Resistant Enterobacteriaceae and Acinetobacter

1054   baumannii. Antimicrob Agents Chemother 60:3840–4.

1055   125.   Gallagher JC. 2019. Omadacycline: A Modernized Tetracycline. Clin Infect Dis 69:S1–S5.

1056   126.   US Food and Drug Administration (FDA). 2010. FDA Drug Safety Communication:

1057   Increased risk of death with Tygacil (tigecycline) compared to other antibiotics used to

1058   treat similar infections. https://www.fda.gov/drugs/drug-safety-and-availability/fda-

1059   drug-safety-communication-increased-risk-death-tygacil-tigecycline-compared-other-

1060   antibiotics (accessed 17th February 2020).

1061 127. Marquez-Ortiz RA, Haggerty L, Olarte N, Duarte C, Garza-Ramos U, Silva-Sanchez J,

1062   Castro BE, Sim EM, Beltran M, Moncada M V., Valderrama A, Castellanos JE, Charles IG,

1063   Vanegas N, Escobar-Perez J, Petty NK. 2017. Genomic Epidemiology of NDM-1-

1064   Encoding Plasmids in Latin American Clinical Isolates Reveals Insights into the Evolution

1065   of Multidrug Resistance. Genome Biol Evol 9:1725–1741.

1066 128. Crandon JL, Nicolau DP. 2013. Human simulated studies of aztreonam and aztreonam-

1067   avibactam to evaluate activity against challenging gram-negative organisms, including

1068   metallo-β-lactamase producers. Antimicrob Agents Chemother 57:3299–306.

1069 129. Shaw E, Rombauts A, Tubau F, Padullés A, Càmara J, Lozano T, Cobo-Sacristán S, Sabe

1070   N, Grau I, Rigo-Bonnin R, Dominguez MA, Carratalà J. 2018. Clinical outcomes after

1071   combination treatment with ceftazidime/avibactam and aztreonam for NDM-1/OXA-

1072   48/CTX-M-15-producing *Klebsiella pneumoniae* infection. J Antimicrob Chemother

1073   73:1104–1106.

1074 130. Davido B, Fellous L, Lawrence C, Maxime V, Rottman M, Dinh A. 2017. Ceftazidime-

1075   Avibactam and Aztreonam, an Interesting Strategy To Overcome β-Lactam Resistance

1076   Conferred by Metallo-β-Lactamases in Enterobacteriaceae and *Pseudomonas*

1077   *aeruginosa*. Antimicrob Agents Chemother 61.

1078 131. Kaye KS, Rice LB, Dane AL, Stus V, Sagan O, Fedosiuk E, Das AF, Skarinsky D, Eckburg

1079   PB, Ellis-Grosse EJ. 2019. Fosfomycin for Injection (ZTI-01) Versus Piperacillin-

1080   tazobactam for the Treatment of Complicated Urinary Tract Infection Including Acute

1081   Pyelonephritis: ZEUS, A Phase 2/3 Randomized Trial. Clin Infect Dis 69:2045–2056.

1082 132. Demir T, Buyukguclu T. 2017. Fosfomycin: *In vitro* efficacy against multidrug-resistant

1083   isolates beyond urinary isolates. J Glob Antimicrob Resist 8:164–168.

1084 133. Albiero J, Mazucheli J, Barros JP dos R, Szczerepa MM dos A, Nishiyama SAB, Carrara-

1085   Marroni FE, Sy S, Fidler M, Sy SKB, Tognim MCB. 2019. Pharmacodynamic Attainment

1086   of the Synergism of Meropenem and Fosfomycin Combination against *Pseudomonas*

1087   *aeruginosa* Producing Metallo-β-Lactamase. Antimicrob Agents Chemother

1088   63(6):e00126-19.

1089   134.   Pharmaceutical Technology. 2016. Allergan and AstraZeneca to develop ATM-AVI for

1090   antibiotic-resistant gram-negative infections. https://www.pharmaceutical-

1091   technology.com/news/newsallergan-astrazeneca-develop-atm-avi-antibiotic-resistant-

1092   gram-negative-infections-4797880/ (accessed 20th February 2020)

1093   135.   U.S. National Library of Medicine. Efficacy, Safety, and Tolerability of ATM-AVI in the

1094   Treatment of Serious Infection Due to MBL-producing Gram-negative Bacteria

1095   NCT03580044. https://clinicaltrials.gov/ct2/show/NCT03580044 (accessed 20th June

1096   2020)

1097   136.   Ehmann DE, Jahić H, Ross PL, Gu R-F, Hu J, Kern G, Walkup GK, Fisher SL. 2012.

1098   Avibactam is a covalent, reversible, non-β-lactam β-lactamase inhibitor. Proc Natl Acad

1099   Sci U S A 109:11663–8.

1100   137.   Livermore DM, Warner M, Mushtaq S. 2013. Activity of MK-7655 combined with

1101   imipenem against Enterobacteriaceae and *Pseudomonas aeruginosa*. J Antimicrob

1102   Chemother 55:390–4.

1103   138.   Sader HS, Mendes RE, Pfaller MA, Shortridge D, Flamm RK, Castanheira M. 2017.

1104   Antimicrobial Activities of Aztreonam-Avibactam and Comparator Agents against

1105   Contemporary (2016) Clinical Enterobacteriaceae Isolates. Antimicrob Agents

1106   Chemother 62(1):e01856-17.

1107   139.   Gregory S, Paul N, Leanne G, Helen B, Angela W, Katrina Y, Chen Z, Jie S, Chow J. 2018.

1108   Clinical Activity of Ceftazidime/Avibactam Against MDR Enterobacteriaceae and

1109   *Pseudomonas Aeruginosa*: Pooled Data From the Ceftazidime/Avibactam Phase III

1110   Clinical Trial Programme. J Antimicrob Chemother 73(9):2519-2523.

1111 140. Wenzler E, Deraedt MF, Harrington AT, Danizger LH. 2017. Synergistic activity of

1112   ceftazidime-avibactam and aztreonam against serine and metallo-β-lactamase-

1113   producing gram-negative pathogens. Diagn Microbiol Infect Dis 88:352–354.

1114 141. NHS Specialist Pharmacy Service. The first stop for professional medicines advice.

1115   Cefiderocol. https://www.sps.nhs.uk/medicines/cefiderocol/

1116   (accessed 20th June 2020)

1117 142. Avery LM, Nicolau DP. 2018. Investigational drugs for the treatment of infections

1118   caused by multidrug-resistant Gram-negative bacteria. Expert Opin Investig Drugs

1119   27:325–338.

1120 143. Portsmouth S, van Veenhuyzen D, Echols R, Machida M, Ferreira JCA, Ariyasu M, Tenke

1121   P, Nagata T Den. 2018. Cefiderocol versus imipenem-cilastatin for the treatment of

1122   complicated urinary tract infections caused by Gram-negative uropathogens: a phase

1123   2, randomised, double-blind, non-inferiority trial. Lancet Infect Dis 18:1319–1328.

1124 144. Kohira N, West J, Ito A, Ito-Horiyama T, Nakamura R, Sato T, Rittenhouse S, Tsuji M,

1125   Yamano Y. 2016. In Vitro Antimicrobial Activity of a Siderophore Cephalosporin, S-

1126   649266, against Enterobacteriaceae Clinical Isolates, Including Carbapenem-Resistant

1127   Strains. Antimicrob Agents Chemother 60:729–734.

1128 145. Saisho Y, Katsube T, White S, Fukase H, Shimada J. 2018. Pharmacokinetics, Safety, and

1129   Tolerability of Cefiderocol, a Novel Siderophore Cephalosporin for Gram-Negative

1130   Bacteria, in Healthy Subjects. Antimicrob Agents Chemother 62:e02163-17.

1131 146. Mushtaq S, Sadouki Z, Vickers A, Livermore D, Woodford N. 2020. In-vitro activity of

1132   cefiderocol against multidrug-resistant Enterobacterales, *Pseudomonas aeruginosa*

1133   and *Acinetobacter baumannii* isolates from the UK. Access Microbiol 2:50.

1134   147.   Matsumoto S, Singley CM, Hoover J, Nakamura R, Echols R, Rittenhouse S, Tsuji M,

1135   Yamano Y. 2017. Efficacy of Cefiderocol against Carbapenem-Resistant Gram-Negative

1136   Bacilli in Immunocompetent-Rat Respiratory Tract Infection Models Recreating Human

1137   Plasma Pharmacokinetics. Antimicrob Agents Chemother 61:e00700-17.

1138   148.   Nakamura R, Ito-Horiyama T, Takemura M, Toba S, Matsumoto S, Ikehara T, Tsuji M,

1139   Sato T, Yamano Y. 2019. In Vivo Pharmacodynamic Study of Cefiderocol, a Novel

1140   Parenteral Siderophore Cephalosporin, in Murine Thigh and Lung Infection Models.

1141   Antimicrob Agents Chemother 63.

1142   149.   Katsube T, Wajima T, Ishibashi T, Arjona Ferreira JC, Echols R. 2017.

1143   Pharmacokinetic/Pharmacodynamic Modeling and Simulation of Cefiderocol, a

1144   Parenteral Siderophore Cephalosporin, for Dose Adjustment Based on Renal Function.

1145   Antimicrob Agents Chemother 61:e01381-16.

1146   150.   Clinical Study of S-649266 for the Treatment of Nosocomial Pneumonia Caused by

1147   Gram-negative Pathogens - NCT03032380.

1148   https://clinicaltrials.gov/ct2/show/NCT03032380 (accessed 13th February 2020)

1149   151.   Study of S-649266 or Best Available Therapy for the Treatment of Severe Infections

1150   Caused by Carbapenem-resistant Gram-negative Pathogens.

1151   https://clinicaltrials.gov/ct2/show/NCT02714595

1152   152.   FDA. 2019. FDA Briefing Document: Cefiderocol Injection. Shionogi, Inc.

1153   https://www.fda.gov/media/131703/download (accessed 13th February 2020)

1154   153.   Reck F, Bermingham A, Blais J, Capka V, Cariaga T, Casarez A, Colvin R, Dean CR, Fekete

1155   A, Gong W, Growcott E, Guo H, Jones AK, Li C, Li F, Lin X, Lindvall M, Lopez S,

1156   McKenney D, Metzger L, Moser HE, Prathapam R, Rasper D, Rudewicz P, Sethuraman

1157   V, Shen X, Shaul J, Simmons RL, Tashiro K, Tang D, Tjandra M, Turner N, Uehara T, Vitt

1158   C, Whitebread S, Yifru A, Zang X, Zhu Q. 2018. Optimization of novel monobactams

1159   with activity against carbapenem-resistant Enterobacteriaceae – Identification of

1160   LYS228. Bioorg Med Chem Lett 28:748–755.

1161   154.   Blais Johanne, Lopez Sara, Li Cindy, Ruzin Alexey, Ranjitkar Srijan, Dean Charles, Leeds

1162   Jennifer, Casarez Anthony, Simmons Robert RF. 2018. In Vitro Activity of LYS228, a

1163   Novel Monobactam Antibiotic, against Multidrug-resistant Enterobacteriaceae.

1164   Antmicrob Agents Chemother 62(10):e00552-18.

1165   155.   Dean CR, Barkan DT, Bermingham A, Blais J, Casey F, Casarez A, Colvin R, Fuller J, Jones

1166   AK, Li C, Lopez S, Metzger LE, Mostafavi M, Prathapam R, Rasper D, Reck F, Ruzin A,

1167   Shaul J, Shen X, Simmons RL, Skewes-Cox P, Takeoka KT, Tamrakar P, Uehara T, Wei J-

1168   R. 2018. Mode of Action of the Monobactam LYS228 and Mechanisms Decreasing In

1169   Vitro Susceptibility in *Escherichia coli* and *Klebsiella pneumoniae*. Antimicrob Agents

1170   Chemother 62:e01200-18.

1171   156.   Livermore DM, Mushtaq S, Warner M, Vickers A, Woodford N. 2017. In vitro activity of

1172   cefepime/zidebactam (WCK 5222) against Gram-negative bacteria. J Antimicrob

1173   Chemother 72:1373–1385.

1174   157.   Mushtaq S, Vickers A, Woodford N, Haldimann A, Livermore DM. 2019. Activity of

1175   nacubactam (RG6080/OP0595) combinations against MBL-producing

1176   Enterobacteriaceae. J Antimicrob Chemother 74:953–960.

1177   158.   Moya B, Barcelo IM, Bhagwat S, Patel M, Bou G, Papp-Wallace KM, Bonomo RA, Oliver

1178   A. 2017. WCK 5107 (Zidebactam) and WCK 5153 Are Novel Inhibitors of PBP2 Showing

1179   Potent "β-Lactam Enhancer" Activity against *Pseudomonas aeruginosa*, Including

1180   Multidrug-Resistant Metallo-β-Lactamase-Producing High-Risk Clones. Antimicrob

1181   Agents Chemother 61(6):e02529-16.

1182   159. Doumith M, Mushtaq S, Livermore DM, Woodford N. 2016. New insights into the

1183   regulatory pathways associated with the activation of the stringent response in

1184   bacterial resistance to the PBP2-targeted antibiotics, mecillinam and OP0595/RG6080.

1185   J Antimicrob Chemother 71:2810–4.

1186   160. Wockhardt. 2019. Wockhardt Annual Report 2018-2019. Mumbai.

1187   161. Cahill ST, Cain R, Wang DY, Lohans CT, Wareham DW, Oswin HP, Mohammed J,

1188   Spencer J, Fishwick CWG, Mcdonough MA, Schofield CJ, Brem J. 2017. Cyclic Boronates

1189   Inhibit All Classes of β-Lactamases. Antimicrob Agents Chemother 61(4):e02260-16.

1190   162. Brem J, Cain R, Cahill S, McDonough MA, Clifton IJ, Jiménez-Castellanos J-C, Avison MB,

1191   Spencer J, Fishwick CWG, Schofield CJ. 2016. Structural basis of metallo-β-lactamase,

1192   serine-β-lactamase and penicillin-binding protein inhibition by cyclic boronates. Nat

1193   Commun 7:12406.

1194   163. Lomovskaya O, Dongxu S, Rubio-Aparicio D, Nelson K, Tsivkovski R, Griffith DC, Dudley

1195   MN. 2017. Vaborbactam: Spectrum of β-Lactamase Inhibition and Impact of

1196   Resistance Mechanisms on Activity in Enterobacteriaceae. Antimicrob Agents

1197   Chemother 61(11):e01443-17.

1198   164. Geilbel B, Dowell J, Dickerson D, Henkel T. 2018. A Randomized, Double-blind, Placebo-

1199   controlled Study of the Safety and Pharmacokinetics of Single and Repeat Doses of

1200   VNRX-5133 in Healthy Subjects. Open Forum Infect Dis 5(Suppl 1): S431.

1201   165. Daigle D, Hamrick J, Chatwin C, Kurepina N, Kreiswirth BN, Shields RK, Oliver A, Clancy

1202   CJ, Nguyen M-H, Pevear D, Xerri L. 2018. 1370. Cefepime/VNRX-5133 Broad-Spectrum

1203   Activity Is Maintained Against Emerging KPC- and PDC-Variants in Multidrug-Resistant

1204   *K. pneumoniae* and *P. aeruginosa*. Open Forum Infect Dis 5:S419–S420.

1205 166. Tsivkovski R, Totrov M, Lomovskaya O. 2020. Biochemical Characterization of

1206   QPX7728, a New Ultrabroad-Spectrum β-Lactamase Inhibitor of Serine and Metallo-β-

1207   Lactamases. Antimicrob Agents Chemother 64.

1208 167. Lomovskaya O, Nelson K, Rubio-Aparicio D, Griffith D, Dudley MN. 2019. QPX7228 In

1209   Vitro Activity in Combination with Oral β-Lactam Antibiotics against

1210   Enterobacteriaceae (ENT) ASM Microbe.

1211 168. Büttner D, Kramer JS, Klingler F-M, Wittmann SK, Hartmann MR, Kurz CG, Kohnhäuser

1212   D, Weizel L, Brüggerhoff A, Frank D, Steinhilber D, Wichelhaus TA, Pogoryelov D,

1213   Proschak E. 2018. Challenges in the Development of a Thiol-Based Broad-Spectrum

1214   Inhibitor for Metallo-β-Lactamases. ACS Infect Dis 4:360–372.

1215 169. Hammond GG, Huber JL, Greenlee ML, Laub JB, Young K, Silver LL, Balkovec JM, Pryor

1216   KD, Wu JK, Leiting B, Pompliano DL, Toney JH. 1999. Inhibition of IMP-1 metallo-β-

1217   lactamases and sensitization of IMP-1-producing bacteria by thioester derivatives.

1218   FEMS Microbiol Lett 179:289–296.

1219 170. Brem J, van Berkel SS, Zollman D, Lee SY, Gileadi O, McHugh PJ, Walsh TR, McDonough

1220   MA, Schofield CJ. 2016. Structural Basis of Metallo-β-Lactamase Inhibition by Captopril

1221   Stereoisomers. Antimicrob Agents Chemother 60:142–150.

1222 171. Tehrani KHME, Martin NI. 2017. Thiol-Containing Metallo-β-Lactamase Inhibitors

1223   Resensitize Resistant Gram-Negative Bacteria to Meropenem. ACS Infect Dis 3:711–

1224   717.

1225 172. González MM, Kosmopoulou M, Mojica MF, Castillo V, Hinchliffe P, Pettinati I, Brem J,

1226   Schofield CJ, Mahler G, Bonomo RA, Llarrull LI, Spencer J, Vila AJ. 2015.

1227   Bisthiazolidines: A Substrate-Mimicking Scaffold as an Inhibitor of the NDM-1

1228   Carbapenemase. ACS Infect Dis 1:544–54.

1229   173.   Hinchliffe P, González MM, Mojica MF, González JM, Castillo V, Saiz C, Kosmopoulou

1230   M, Tooke CL, Llarrull LI, Mahler G, Bonomo RA, Vila AJ, Spencer J. 2016. Cross-class

1231   metallo-β-lactamase inhibition by bisthiazolidines reveals multiple binding modes. Proc

1232   Natl Acad Sci 113:E3745–E3754.

1233   174.   Lambert RJW, Hanlon GW, Denyer SP. 2004. The synergistic effect of

1234   EDTA/antimicrobial combinations on *Pseudomonas aeruginosa*. J Appl Microbiol

1235   96:244–53.

1236   175.   Vaara M. 1992. Agents that increase the permeability of the outer membrane.

1237   Microbiol Rev 56:395–411.

1238   176.   Aoki N, Ishii Y, Tateda K, Saga T, Kimura S, Kikuchi Y, Kobayashi T, Tanabe Y, Tsukada H,

1239   Gejyo F, Yamaguchi K. 2010. Efficacy of calcium-EDTA as an inhibitor for metallo-β-

1240   lactamase in a mouse model of *Pseudomonas aeruginosa* pneumonia. Antimicrob

1241   Agents Chemother 54:4582–8.

1242   177.   Yoshizumi A, Ishii Y, Kimura S, Saga T, Harada S, Yamaguchi K, Tateda K, Livermore DM,

1243   Woodford N, Livermore DM. 2013. Efficacies of calcium–EDTA in combination with

1244   imipenem in a murine model of sepsis caused by *Escherichia coli* with NDM-1 β-

1245   lactamase. J Infect Chemother 19:992–995.

1246   178.   Patil UN, Jambulingappa KL. 2015. A Combination Strategy of Ceftriaxone, Sulbactam

1247   and Disodium Edetate for the Treatment of Multi-Drug Resistant (MDR) Septicaemia: A

1248   Retrospective, Observational Study in Indian Tertiary Care Hospital. J Clin Diagn Res

1249   9:FC29-32.

1250   179.   A Journal of Elores Publications.

1251   http://pop.venuspharmagmbh.de/images/Elores_Abstract_Booklet.pdf

1252   180.   U.S. Department of Health & Human Sciences. 2019. Code of Federal Regulations Food

1253   and Drugs. Title 21, Volume 1.

1254   https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=73.2120

1255   (accessed 24th June 2020)

1256   181.   Graceway Pharmaceuticals. 2009. Calcium Disodium Versenate: NDA 8-922/S-016.

1257   https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/008922s016lbl.pdf

1258   (accessed 24th June 2020)

1259   182.   Haenni AL, Robert M, Vetter W, Roux L, Barbier M, Lederer E. 1965. Structure

1260   chimique des aspergillomarasmines A et B. Helv Chim Acta 48:729–750.

1261   183.   Bergstrom A, Katko A, Adkins Z, Hill J, Cheng Z, Burnett M, Yang H, Aitha M, Mehaffey

1262   MR, Brodbelt JS, Tehrani KHME, Martin NI, Bonomo RA, Page RC, Tierney DL, Fast W,

1263   Wright GD, Crowder MW. 2018. Probing the interaction of Aspergillomarasmine A

1264   (AMA) with metallo-β-lactamases NDM-1, VIM-2, and IMP-7. ACS Infect Dis 4:135.

1265   184.   King AM, Reid-Yu SA, Wang W, King DT, De Pascale G, Strynadka NC, Walsh TR,

1266   Coombes BK, Wright GD. 2014. Aspergillomarasmine A overcomes metallo-β-

1267   lactamase antibiotic resistance. Nature 510:503–6.

1268   185.   VenatoRx Pharmaceuticals Press Release. 2019. https://www.venatorx.com/press-

1269   releases/venatorx-pharmaceuticals-to-present-data-for-its-injectable-and-orally-

1270   bioavailable-beta-lactamase-inhibitor-drug-candidates-at-eccmid-2019/ (accessed 9th

1271   February 2020)

1272   186.   Ghazi IM, Crandon JL, Lesho EP, McGann P, Nicolau DP. 2015. Efficacy of Humanized

1273   High-Dose Meropenem, Cefepime, and Levofloxacin against Enterobacteriaceae

1274   Isolates Producing Verona Integron-Encoded Metallo-β-Lactamase (VIM) in a Murine

1275   Thigh Infection Model. Antimicrob Agents Chemother 59:7145.

1276   187.   Wiskirchen DE, Nordmann P, Crandon JL, Nicolau DP. 2014. In vivo efficacy of human

1277   simulated regimens of carbapenems and comparator agents against NDM-1-producing

1278   Enterobacteriaceae. Antimicrob Agents Chemother 58:1671–7.

1279   188.   MacVane SH, Crandon JL, Nichols WW, Nicolau DP. 2014. Unexpected in vivo activity

1280   of ceftazidime alone and in combination with avibactam against New Delhi metallo-β-

1281   lactamase-producing Enterobacteriaceae in a murine thigh infection model.

1282   Antimicrob Agents Chemother 58:7007–9.

1283

1284   Table 1 Examples of chromosomal and plasmid-associated MBLs (11)

1285

Chromosomal MBLs			Plasmid-associated MBLs	
Species	Enzyme	Subclass	Enzyme	Subclass
Bacillus cereus	BcII	**B1**	Verona integron-encoded (VIM)	**B1**
Chryseobacterium indologenes	IND	**B1**	New-Delhi metallo-β-lactamase (NDM)	**B1**
Elizabethkingia meningoseptica	BlaB	**B1**	Imipenemase (IMP)	**B1**
Myroides odoratimimus	MUS/ MYO	**B1**	Sao Paulo metallo-β-lactamase (SPM)	**B1**
Bacteriodes fragilis*	CfiA / CcrA	**B1**	German imipenemase (GIM)	**B1**
Aeromonas spp.	CphA	**B2**	KHM	**B1**
Stenotrophomonas maltophilia	L1	**B3**	Dutch imipenemase (DIM)	**B1**
Elizabethkingia meningoseptica	GOB	**B3**	Adelaide Imipenemase (AIM)	**B1**

1286

1287   *Unlike most other chromosomal MBLs, the *Bacteroides fragilis* enzyme is rare in the species

1288

1289

Figure 1. Structure of amino acid residues in metallo-β-lactamase enzyme subclasses (8)

(Reproduced with permission from John Wiley and Sons Publishers, sourced from Palzkill T et al. 2013. Metallo-β-lactamase structure and function. Ann N Y Acad Sci 1277:91–104)

Figure 1 illustrates the amino acid residues that bind zinc at the active sites of B1, B2, and B3 MBLs. Crystal structures of B1 enzymes, including IMP-, VIM-, NDM-, and *B. fragilis* CcrA, (panel A) reveal two zinc-binding sites (Zn1 and Zn2). The Zn1 site contains three histidine residues (His116, His118, and His196), whereas the ligands for the Zn2 site are aspartic acid (Asp120), cysteine (Cys221), and histidine (His263). There is only one zinc ion in the active site of the *A. hydrophila* enzyme (subclass B2, panel B), and two in the active site of the *S. maltophilia* enzyme (subclass B3, panel C).

Figure 2. Global distribution of acquired metallo-β-lactamases

Panel A, Enterobacterales

NDM
VIM
IMP
SPM

Full-tone color is used when the indicated MBL is the most prevalent carbapenemase in the country. The

lighter tone is used to indicate the most prevalent MBL group in countries where serine carbapenemases

(KPC or OXA-48-like) are more prevalent. Panel A, Enterobacterales; Panel B, *P. aeruginosa*

1309

1310

Panel B, *P. aeruginosa*

*In the USA there are just a few reports of *P. aeruginosa* with either IMP or VIM MBLs

1311